MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH: Form 990, tax year 2011

View the entire original 990 at ProPublica ↗

Organization: MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH (EIN 13-4141945)
Tax period: 2011-01-01 to 2011-12-31
Filed: 2012-05-16
IRS object ID: 201201379349300835
Schema version: 2011v1.2
Source: Download XML · Original 990 at ProPublica

Every field in the e-filed return. Faint text is the IRS element name, for citing.

Return header
Form 990
Schedule A
Schedule B
Schedule D
Schedule F
Schedule G
Schedule I
Schedule J
Schedule L
Schedule M
Schedule O
Schedule R

Return header ReturnHeader

Field	Value	IRS element (for citing)
Timestamp	2012-05-16T13:13:13-05:00	Timestamp
Tax Period End Date	2011-12-31	TaxPeriodEndDate

Preparer Firm PreparerFirm

Preparer Firm Business Name PreparerFirmBusinessName

Field	Value	IRS element (for citing)
Business Name Line1	EISNERAMPER LLP	BusinessNameLine1

Preparer Firm US Address PreparerFirmUSAddress

Field	Value	IRS element (for citing)
Address Line1	750 THIRD AVENUE	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	100172703	ZIPCode

Field	Value	IRS element (for citing)
Return Type	990	ReturnType
Tax Period Begin Date	2011-01-01	TaxPeriodBeginDate

Filer Filer

Field	Value	IRS element (for citing)
EIN	134141945	EIN

Name Name

Field	Value	IRS element (for citing)
Business Name Line1	THE MICHAEL J FOX FOUNDATION	BusinessNameLine1
Business Name Line2	FOR PARKINSON'S RESEARCH	BusinessNameLine2

Field	Value	IRS element (for citing)
In Care Of Name	% % STEPHEN GRUBB - MJFF	InCareOfName
Name Control	MICH	NameControl
Phone	2125090995	Phone

US Address USAddress

Field	Value	IRS element (for citing)
Address Line1	GRAND CENTRAL STATION P O BOX 47	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	101634777	ZIPCode

Officer Officer

Field	Value	IRS element (for citing)
Name	Joanne Martz	Name
Title	Chief Financial & Admin Officer	Title
Date Signed	2012-05-15	DateSigned
Authorize Third Party	true	AuthorizeThirdParty

Preparer Preparer

Field	Value	IRS element (for citing)
Phone	2129498700	Phone

Field	Value	IRS element (for citing)
Tax Year	2011	TaxYear
Build TS	2016-02-24 21:20:13Z	BuildTS

Form 990 IRS990

Field	Value	IRS element (for citing)
Address Change	X	AddressChange
Name Of Principal Officer Person	Todd Sherer	NameOfPrincipalOfficerPerson

Address Principal Officer US AddressPrincipalOfficerUS

Field	Value	IRS element (for citing)
Address Line1	GRAND CENTRAL STATION P O 4777	AddressLine1
City	New York	City
State	NY	State
ZIP Code	101634777	ZIPCode

Field	Value	IRS element (for citing)
Gross Receipts	67216814	GrossReceipts
Group Return For Affiliates	false	GroupReturnForAffiliates
Organization501c3	X	Organization501c3
Web Site	www.michaeljfox.org	WebSite
Type Of Organization Corporation	X	TypeOfOrganizationCorporation
Year Formation	2000	YearFormation
State Legal Domicile	DE	StateLegalDomicile
Activity Or Mission Description	THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA.	ActivityOrMissionDescription
Nbr Voting Members Governing Body	28	NbrVotingMembersGoverningBody
Nbr Independent Voting Members	27	NbrIndependentVotingMembers
Total Nbr Employees	78	TotalNbrEmployees
Total Nbr Volunteers	17	TotalNbrVolunteers
Total Gross UBI	22042	TotalGrossUBI
Net Unrelated Business Txbl Income	2119	NetUnrelatedBusinessTxblIncome
Contributions Grants Prior Year	57111106	ContributionsGrantsPriorYear
Contributions Grants Current Year	64970818	ContributionsGrantsCurrentYear
Program Service Revenue Prior Year	0	ProgramServiceRevenuePriorYear
Program Service Revenue CY	0	ProgramServiceRevenueCY
Investment Income Prior Year	476177	InvestmentIncomePriorYear
Investment Income Current Year	174041	InvestmentIncomeCurrentYear
Other Revenue Prior Year	34177	OtherRevenuePriorYear
Other Revenue Current Year	38514	OtherRevenueCurrentYear
Total Revenue Prior Year	57621460	TotalRevenuePriorYear
Total Revenue Current Year	65183373	TotalRevenueCurrentYear
Grants And Similar Amnts Prior Year	49441851	GrantsAndSimilarAmntsPriorYear
Grants And Similar Amnts CY	53857613	GrantsAndSimilarAmntsCY
Benefits Paid To Members Prior Year	0	BenefitsPaidToMembersPriorYear
Benefits Paid To Members CY	0	BenefitsPaidToMembersCY
Salaries Etc Prior Year	6107055	SalariesEtcPriorYear
Salaries Etc Current Year	6906870	SalariesEtcCurrentYear
Total Prof Fundrsng Exp Prior Year	49600	TotalProfFundrsngExpPriorYear
Total Prof Fundrsng Exp CY	60000	TotalProfFundrsngExpCY
Total Fundrsng Exp Current Year	4305375	TotalFundrsngExpCurrentYear
Other Expense Prior Year	4458038	OtherExpensePriorYear
Other Expenses Current Year	4814498	OtherExpensesCurrentYear
Total Expenses Prior Year	60056544	TotalExpensesPriorYear
Total Expenses Current Year	65638981	TotalExpensesCurrentYear
Revenues Less Expenses Prior Year	-2435084	RevenuesLessExpensesPriorYear
Revenues Less Expenses CY	-455608	RevenuesLessExpensesCY
Total Assets BOY	78224899	TotalAssetsBOY
Total Assets EOY	95542240	TotalAssetsEOY
Total Liabilities BOY	56636725	TotalLiabilitiesBOY
Total Liabilities EOY	74420395	TotalLiabilitiesEOY
Net Assets Or Fund Balances BOY	21588174	NetAssetsOrFundBalancesBOY
Net Assets Or Fund Balances EOY	21121845	NetAssetsOrFundBalancesEOY
Mission Description	THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH IS DEDICATED TO ENSURING THE DEVELOPMENT OF BETTER TREATMENTS, AND ULTIMATELY A CURE, FOR PARKINSON'S DISEASE THROUGH AN AGRESSIVELY FUNDED RESEARCH AGENDA.	MissionDescription
Significant New Program Services	false	SignificantNewProgramServices
Significant Change	false	SignificantChange
Expense	59753896	Expense
Grants	53857613	Grants
Description	TO FUND RESEARCH FOCUSED ON DEVELOPING A CURE FOR PARKINSON'S DISEASE.	Description
Total Program Service Expense	59753896	TotalProgramServiceExpense
Described In501 C3	true	DescribedIn501C3
Schedule B Required	true	ScheduleBRequired
Political Activities	false	PoliticalActivities
Lobbying Activities	false	LobbyingActivities
Donor Advised Funds	false	DonorAdvisedFunds
Conservation Easements	false	ConservationEasements
Collections Of Art	false	CollectionsOfArt
Credit Counseling	false	CreditCounseling
Term Or Permanent Endowments	false	TermOrPermanentEndowments
Report Land Bldg Equip	true	ReportLandBldgEquip
Report Invest Oth Securities	false	ReportInvestOthSecurities
Report Prog Rel Invest	false	ReportProgRelInvest
Report Other Assets	false	ReportOtherAssets
Report Other Liabilities	true	ReportOtherLiabilities
Report Fin48 Footnote	true	ReportFin48Footnote
Independent Audit Financial Stmt	false	IndependentAuditFinancialStmt
Consolidated Audit Financial Stmt	true	ConsolidatedAuditFinancialStmt
School	false	School
Foreign Office	true	ForeignOffice
Foreign Activities	true	ForeignActivities
More Than5000 K To Organizations	true	MoreThan5000KToOrganizations
More Than5000 K To Individuals	true	MoreThan5000KToIndividuals
Professional Fundraising	true	ProfessionalFundraising
Fundraising Activities	true	FundraisingActivities
Gaming	false	Gaming
Hospital	false	Hospital
Grants To Organizations	true	GrantsToOrganizations
Grants To Individuals	false	GrantsToIndividuals
Schedule J Required	true	ScheduleJRequired
Tax Exempt Bonds	false	TaxExemptBonds
Excess Benefit Transaction	false	ExcessBenefitTransaction
Prior Excess Benefit Transaction	false	PriorExcessBenefitTransaction
Loan To Officer Or DQP	false	LoanToOfficerOrDQP
Grant To Related Person	false	GrantToRelatedPerson
Bsnss Rltnshp With Organization	false	BsnssRltnshpWithOrganization
Bsnss Rltnshp Thru Family Member	false	BsnssRltnshpThruFamilyMember
Officer Entity With Bsnss Rltnshp	true	OfficerEntityWithBsnssRltnshp
Deductible Non Cash Contributions	true	DeductibleNonCashContributions
Deductible Contributions Of Art	false	DeductibleContributionsOfArt
Terminated	false	Terminated
Partial Liquidation	false	PartialLiquidation
Disregarded Entity	false	DisregardedEntity
Related Entity	true	RelatedEntity
Related Org Controlled Entity	false	RelatedOrgControlledEntity
Transaction Related Entity	false	TransactionRelatedEntity
Transfers To Exempt Non Chrtbl Org	false	TransfersToExemptNonChrtblOrg
Activities Conducted Partnership	false	ActivitiesConductedPartnership
Schedule O Required	true	ScheduleORequired
Number Forms Transmitted With1096	125	NumberFormsTransmittedWith1096
Number W2 G Included	0	NumberW2GIncluded
Compliance With Backup Witholding	true	ComplianceWithBackupWitholding
Number Of Employees	78	NumberOfEmployees
Employment Tax Returns Filed	true	EmploymentTaxReturnsFiled
Unrelated Business Income	true	UnrelatedBusinessIncome
Form990-T Filed	true	Form990-TFiled
Foreign Financial Account	true	ForeignFinancialAccount
Name Of Foreign Country	CA	NameOfForeignCountry
Prohibited Tax Shelter Trans	false	ProhibitedTaxShelterTrans
Taxable Party Notification	false	TaxablePartyNotification
Non Deductible Contributions	false	NonDeductibleContributions
Quid Pro Quo Contributions	true	QuidProQuoContributions
Quid Pro Quo Disclosure	true	QuidProQuoDisclosure
Form8282 Property Disposed Of	false	Form8282PropertyDisposedOf
Funds To Pay Premiums	false	FundsToPayPremiums
Premiums Paid	false	PremiumsPaid
Indoor Tanning Services	false	IndoorTanningServices
Info In Schedule O Part VI	X	InfoInScheduleOPartVI
Nbr Voting Governing Body Members	28	NbrVotingGoverningBodyMembers
Number Independent Voting Members	27	NumberIndependentVotingMembers
Family Or Business Relationship	true	FamilyOrBusinessRelationship
Delegation Of Management Duties	false	DelegationOfManagementDuties
Changes To Organizing Docs	false	ChangesToOrganizingDocs
Material Diversion Or Misuse	false	MaterialDiversionOrMisuse
Members Or Stockholders	false	MembersOrStockholders
Election Of Board Members	false	ElectionOfBoardMembers
Decisions Subject To Approval	false	DecisionsSubjectToApproval
Minutes Of Governing Body	true	MinutesOfGoverningBody
Minutes Of Committees	true	MinutesOfCommittees
Officer Mailing Address	false	OfficerMailingAddress
Local Chapters	false	LocalChapters
Form990 Provided To Governing Body	true	Form990ProvidedToGoverningBody
Conflict Of Interest Policy	true	ConflictOfInterestPolicy
Annual Disclosure Covered Persons	true	AnnualDisclosureCoveredPersons
Regular Monitoring Enforcement	true	RegularMonitoringEnforcement
Whistleblower Policy	true	WhistleblowerPolicy
Document Retention Policy	true	DocumentRetentionPolicy
Compensation Process CEO	true	CompensationProcessCEO
Compensation Process Other	true	CompensationProcessOther
Investment In Joint Venture	false	InvestmentInJointVenture
States Where Copy Of Return Is Filed	AL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AZ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	AR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CO	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	CT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	FL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	GA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	IL	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	KY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ME	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MD	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	MS	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NJ	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NM	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NY	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	NC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	ND	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OH	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OK	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	OR	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	PA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	RI	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	SC	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	TN	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	UT	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	VA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WA	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WV	StatesWhereCopyOfReturnIsFiled
States Where Copy Of Return Is Filed	WI	StatesWhereCopyOfReturnIsFiled
Upon Request	X	UponRequest

The Books Are In Care Of TheBooksAreInCareOf

Field	Value	IRS element (for citing)
Name Person	STEPHEN GRUBB - MJFF	NamePerson
Telephone Number	2125090995	TelephoneNumber

Address US AddressUS

Field	Value	IRS element (for citing)
Address Line1	GRAND CENTRAL STATION PO BOX 4777	AddressLine1
City	NEW YORK	City
State	NY	State
ZIP Code	101634777	ZIPCode

Field	Value	IRS element (for citing)
Info In Schedule O Part VII	X	InfoInScheduleOPartVII

Form990 Part VII Section A Form990PartVIISectionA (39 entries)

TitleTitle	Average Hours Per WeekAverageHoursPerWeek	Individual Trustee Or DirectorIndividualTrusteeOrDirector	Reportable Comp From OrganizationReportableCompFromOrganization	Reportable Comp From Related OrgsReportableCompFromRelatedOrgs	Other CompensationOtherCompensation	OfficerOfficer	Key EmployeeKeyEmployee	Highest Compensated EmployeeHighestCompensatedEmployee
Michael J Fox
Founder	2.0	X	0	0	0
Robert W Shackleton
Chairman	2.0	X	0	0	0	X
George E Prescott
Vice Chariman	2.0	X	0	0	0	X
Fred G Weiss
Treasurer	2.0	X	0	0	0	X
Holly S Andersen MD
Member	2.0	X	0	0	0
Eva Andersson-Dubin MD
Member	2.0	X	0	0	0
Jon Brooks
Member	2.0	X	0	0	0
Mark Booth
Member	2.0	X	0	0	0
Barry J Cohen
Member	2.0	X	0	0	0
Donny Deutsch
Member	2.0	X	0	0	0
David Einhorn
Member	2.0	X	0	0	0
Karen Finerman
Member	2.0	X	0	0	0
Nelle Fortenberry
Member	2.0	X	0	0	0
Albert B Glickman
Member	2.0	X	0	0	0
David Golub
Member	2.0	X	0	0	0
Mark L Hart III
Member	2.0	X	0	0	0
Skip Irving
Member	2.0	X	0	0	0
Edward Kalikow
Member	2.0	X	0	0	0
Katheen Kennedy
Member	2.0	X	0	0	0
Edwin A Levy
Member	2.0	X	0	0	0
Marc S Lipschultz
Member	2.0	X	0	0	0
Douglas IOstrover
Member	2.0	X	0	0	0
Tracy Pollan
Member	2.0	X	0	0	0
Ryan Reynolds
Member	2.0	X	0	0	0
Frederick E Rowe Jr
Member	2.0	X	0	0	0
Lily Safra
Member	2.0	X	0	0	0
Curtis Schenker
Member	2.0	X	0	0	0
George Whelen
Member	2.0	X	0	0	0
Katherine H Hood
Former CEO	40.0		276684	0	7350	X
Todd Sherer
CEO	40.0		388891	0	24653	X
Joanne Martz
Chief Finan and Admin Officer	40.0		279121	0	22236	X
Deborah W Brooks
Co-Founder	40.0		474377	0	28402		X
Sohini Chowdhury
VP, Research Partnerships	40.0		230026	0	13709		X
Sheila Kelly
Deputy Director, Advancement	40.0		167951	0	11847		X
Holly Barkhymer
VP, Marketing & Communications	40.0		135104	0	14069			X
Brian K Fiske
Director, Research Programs	40.0		176149	0	19901			X
Mark A Frasier
Director, Research Programs	40.0		168750	0	5063			X
Alison Urkowitz
Director, Research Operations	40.0		136340	0	10898			X
Laxmi Wordham
Chief Digital Officer	40.0		130912	0	17962			X

Field	Value	IRS element (for citing)
Total Reportable Comp From Org	2564305	TotalReportableCompFromOrg
Total Reportable Comp Frm Rltd Orgs	0	TotalReportableCompFrmRltdOrgs
Total Other Compensation	176090	TotalOtherCompensation
Number Individuals GT100 K	17	NumberIndividualsGT100K
Formers Listed	false	FormersListed
Total Comp GT150 K	true	TotalCompGT150K
Compensation From Other Sources	false	CompensationFromOtherSources

Contractor Compensation ContractorCompensation (2 entries)

Address Line1AddressOfContractor/AddressUS/AddressLine1	CityAddressOfContractor/AddressUS/City	StateAddressOfContractor/AddressUS/State	ZIP CodeAddressOfContractor/AddressUS/ZIPCode	Description Of ServicesDescriptionOfServices	CompensationCompensation
SCHANER AND LUBITZ LLC
6391 ARLINGTIN ROAD SUITE 200	BETHESDA	MD	20814	Legal Advice	130000
EIGHT SQUARE ACCOUNTING
666 BROADWAY SUITE 830	NEW YORK	NY	10012	Accounting Services	140000

Field	Value	IRS element (for citing)
Number Of Contractors GT100 K	2	NumberOfContractorsGT100K
Fundraising Events	4651256	FundraisingEvents
Related Organizations	2277800	RelatedOrganizations
All Other Contributions	58041762	AllOtherContributions
Total Contributions	64970818	TotalContributions
Total Program Service Revenue	0	TotalProgramServiceRevenue

Investment Income InvestmentIncome

Field	Value	IRS element (for citing)
Total Revenue Column	42326	TotalRevenueColumn
Exclusion	$42,326	ExclusionAmount

Income From Invest Bond Proceeds IncomeFromInvestBondProceeds

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Royalties Revenue RoyaltiesRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Gross Amount Sales Assets GrossAmountSalesAssets

Field	Value	IRS element (for citing)
Securities	1338698	Securities

Less Cost Oth Basis Sales Expenses LessCostOthBasisSalesExpenses

Field	Value	IRS element (for citing)
Securities	1206983	Securities

Gain Or Loss GainOrLoss

Field	Value	IRS element (for citing)
Securities	131715	Securities

Net Gain Or Loss Investments NetGainOrLossInvestments

Field	Value	IRS element (for citing)
Total Revenue Column	131715	TotalRevenueColumn
Exclusion	$131,715	ExclusionAmount

Field	Value	IRS element (for citing)
Gross Income Fundraising Events	795484	GrossIncomeFundraisingEvents
Cntrbtns Rprtd Fundraising Events	4651256	CntrbtnsRprtdFundraisingEvents
Fundraising Direct Expenses	795484	FundraisingDirectExpenses

Net Income From Fundraising Events NetIncomeFromFundraisingEvents

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Net Income From Gaming NetIncomeFromGaming

Field	Value	IRS element (for citing)
Total Revenue Column	0	TotalRevenueColumn

Field	Value	IRS element (for citing)
Gross Sales Of Inventory	53016	GrossSalesOfInventory
Cost Of Goods Sold	30974	CostOfGoodsSold

Net Income Or Loss NetIncomeOrLoss

Field	Value	IRS element (for citing)
Total Revenue Column	22042	TotalRevenueColumn
Unrelated Business Revenue	22042	UnrelatedBusinessRevenue

Other Revenue Misc OtherRevenueMisc

Field	Value	IRS element (for citing)
Description	MISCELLANEOUS REVENUE	Description
Business Code	900099	BusinessCode
Total Revenue Column	16472	TotalRevenueColumn
Exclusion	$16,472	ExclusionAmount

Field	Value	IRS element (for citing)
Total Other Revenue	16472	TotalOtherRevenue

Total Revenue TotalRevenue

Field	Value	IRS element (for citing)
Total Revenue Column	65183373	TotalRevenueColumn
Unrelated Business Revenue	22042	UnrelatedBusinessRevenue
Exclusion	$190,513	ExclusionAmount

Grants To Domestic Orgs GrantsToDomesticOrgs

Field	Value	IRS element (for citing)
Total	36887394	Total
Program Services	36887394	ProgramServices

Grants To Domestic Individuals GrantsToDomesticIndividuals

Field	Value	IRS element (for citing)
Total	0	Total
Program Services	0	ProgramServices

Foreign Grants ForeignGrants

Field	Value	IRS element (for citing)
Total	16970219	Total
Program Services	16970219	ProgramServices

Benefits To Members BenefitsToMembers

Field	Value	IRS element (for citing)
Total	0	Total

Comp Current Officers Directors CompCurrentOfficersDirectors

Field	Value	IRS element (for citing)
Total	1925247	Total
Program Services	958546	ProgramServices
Management And General	299531	ManagementAndGeneral
Fundraising	667170	Fundraising

Comp Disqual Persons CompDisqualPersons

Field	Value	IRS element (for citing)
Total	0	Total

Other Salaries And Wages OtherSalariesAndWages

Field	Value	IRS element (for citing)
Total	3871227	Total
Program Services	1927415	ProgramServices
Management And General	602288	ManagementAndGeneral
Fundraising	1341524	Fundraising

Pension Plan Contributions PensionPlanContributions

Field	Value	IRS element (for citing)
Total	158318	Total
Program Services	72655	ProgramServices
Management And General	28785	ManagementAndGeneral
Fundraising	56878	Fundraising

Other Employee Benefits OtherEmployeeBenefits

Field	Value	IRS element (for citing)
Total	579702	Total
Program Services	266035	ProgramServices
Management And General	105399	ManagementAndGeneral
Fundraising	208268	Fundraising

Payroll Taxes PayrollTaxes

Field	Value	IRS element (for citing)
Total	372376	Total
Program Services	170889	ProgramServices
Management And General	67704	ManagementAndGeneral
Fundraising	133783	Fundraising

Fees For Services Management FeesForServicesManagement

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Legal FeesForServicesLegal

Field	Value	IRS element (for citing)
Total	129174	Total
Program Services	32490	ProgramServices
Management And General	18129	ManagementAndGeneral
Fundraising	78555	Fundraising

Fees For Services Accounting FeesForServicesAccounting

Field	Value	IRS element (for citing)
Total	185100	Total
Management And General	185100	ManagementAndGeneral

Fees For Services Lobbying FeesForServicesLobbying

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Prof Fundraising FeesForServicesProfFundraising

Field	Value	IRS element (for citing)
Total	60000	Total
Fundraising	60000	Fundraising

Fees For Services Invst Mgmnt Fees FeesForServicesInvstMgmntFees

Field	Value	IRS element (for citing)
Total	0	Total

Fees For Services Other FeesForServicesOther

Field	Value	IRS element (for citing)
Total	623748	Total
Program Services	527702	ProgramServices
Fundraising	96046	Fundraising

Advertising Advertising

Field	Value	IRS element (for citing)
Total	116271	Total
Program Services	53258	ProgramServices
Fundraising	63013	Fundraising

Office Expenses OfficeExpenses

Field	Value	IRS element (for citing)
Total	664437	Total
Program Services	238538	ProgramServices
Management And General	47715	ManagementAndGeneral
Fundraising	378184	Fundraising

Information Technology InformationTechnology

Field	Value	IRS element (for citing)
Total	268823	Total
Program Services	134094	ProgramServices
Management And General	25552	ManagementAndGeneral
Fundraising	109177	Fundraising

Royalties Royalties

Field	Value	IRS element (for citing)
Total	0	Total

Occupancy Occupancy

Field	Value	IRS element (for citing)
Total	573023	Total
Program Services	294422	ProgramServices
Management And General	87642	ManagementAndGeneral
Fundraising	190959	Fundraising

Travel Travel

Field	Value	IRS element (for citing)
Total	353760	Total
Program Services	120204	ProgramServices
Management And General	13672	ManagementAndGeneral
Fundraising	219884	Fundraising

Travel Entrtnmnt Public Officials TravelEntrtnmntPublicOfficials

Field	Value	IRS element (for citing)
Total	0	Total

Conferences Meetings ConferencesMeetings

Field	Value	IRS element (for citing)
Total	944626	Total
Program Services	944626	ProgramServices

Interest Interest

Field	Value	IRS element (for citing)
Total	50916	Total
Management And General	50916	ManagementAndGeneral

Payments To Affiliates PaymentsToAffiliates

Field	Value	IRS element (for citing)
Total	0	Total

Depreciation Depletion DepreciationDepletion

Field	Value	IRS element (for citing)
Total	135640	Total
Program Services	71188	ProgramServices
Management And General	18230	ManagementAndGeneral
Fundraising	46222	Fundraising

Insurance Insurance

Field	Value	IRS element (for citing)
Total	60178	Total
Program Services	48722	ProgramServices
Management And General	3513	ManagementAndGeneral
Fundraising	7943	Fundraising

Other Expenses OtherExpenses (4 entries)

DescriptionDescription	TotalTotal	Program ServicesProgramServices	Management And GeneralManagementAndGeneral	FundraisingFundraising
CREDIT CARD & BROKERAGE FEES	212400	268	15922	196210
OTHER SPECIAL EVENTS EXPENSE	187701			187701
DONATION PROCESSING	92986			92986
MARATHON RUNNER FEES	150872			150872

All Other Expenses AllOtherExpenses

Field	Value	IRS element (for citing)
Total	64843	Total
Program Services	35231	ProgramServices
Management And General	9612	ManagementAndGeneral
Fundraising	20000	Fundraising

Total Functional Expenses TotalFunctionalExpenses

Field	Value	IRS element (for citing)
Total	65638981	Total
Program Services	59753896	ProgramServices
Management And General	1579710	ManagementAndGeneral
Fundraising	4305375	Fundraising

Cash Non Interest Bearing CashNonInterestBearing

Field	Value	IRS element (for citing)
BOY	1724	BOY
EOY	104	EOY

Savings And Temp Cash Investments SavingsAndTempCashInvestments

Field	Value	IRS element (for citing)
BOY	47584331	BOY
EOY	80371171	EOY

Pledges And Grants Receivable PledgesAndGrantsReceivable

Field	Value	IRS element (for citing)
BOY	28467039	BOY
EOY	12027926	EOY

Accounts Receivable AccountsReceivable

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Receivables From Officers Etc ReceivablesFromOfficersEtc

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Receivables From Disqual Persons ReceivablesFromDisqualPersons

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Notes Loans Receivable Net OtherNotesLoansReceivableNet

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Inventories For Sale Or Use InventoriesForSaleOrUse

Field	Value	IRS element (for citing)
BOY	22872	BOY
EOY	17847	EOY

Prepaid Expenses Deferred Charges PrepaidExpensesDeferredCharges

Field	Value	IRS element (for citing)
BOY	310926	BOY
EOY	303256	EOY

Field	Value	IRS element (for citing)
Land Buildings Equipment Basis	1673002	LandBuildingsEquipmentBasis
Land Bldg Equipment Accum Deprec	1019579	LandBldgEquipmentAccumDeprec

Land Buildings Equipment Basis Net LandBuildingsEquipmentBasisNet

Field	Value	IRS element (for citing)
BOY	337060	BOY
EOY	653423	EOY

Investments Pub Traded Securities InvestmentsPubTradedSecurities

Field	Value	IRS element (for citing)
BOY	1467886	BOY
EOY	1339815	EOY

Investments Other Securities InvestmentsOtherSecurities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Investments Program Related InvestmentsProgramRelated

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Intangible Assets IntangibleAssets

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Other Assets Total OtherAssetsTotal

Field	Value	IRS element (for citing)
BOY	33061	BOY
EOY	828698	EOY

Total Assets TotalAssets

Field	Value	IRS element (for citing)
BOY	78224899	BOY
EOY	95542240	EOY

Accounts Payable Accrued Expenses AccountsPayableAccruedExpenses

Field	Value	IRS element (for citing)
BOY	1542594	BOY
EOY	1590225	EOY

Grants Payable GrantsPayable

Field	Value	IRS element (for citing)
BOY	53453069	BOY
EOY	56245521	EOY

Deferred Revenue DeferredRevenue

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	14898701	EOY

Tax Exempt Bond Liabilities TaxExemptBondLiabilities

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Escrow Account Liability EscrowAccountLiability

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Loans From Officers Directors LoansFromOfficersDirectors

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Mort Notes Pybl Secured Invest Prop MortNotesPyblSecuredInvestProp

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Unsecured Notes Loans Payable UnsecuredNotesLoansPayable

Field	Value	IRS element (for citing)
BOY	1000196	BOY
EOY	1000196	EOY

Other Liabilities OtherLiabilities

Field	Value	IRS element (for citing)
BOY	640866	BOY
EOY	685752	EOY

Total Liabilities TotalLiabilities

Field	Value	IRS element (for citing)
BOY	56636725	BOY
EOY	74420395	EOY

Field	Value	IRS element (for citing)
Follow SFAS117	X	FollowSFAS117

Unrestricted Net Assets UnrestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	4179853	BOY
EOY	5774290	EOY

Temporarily Restricted Net Assets TemporarilyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	17408321	BOY
EOY	15347555	EOY

Permanently Restricted Net Assets PermanentlyRestrictedNetAssets

Field	Value	IRS element (for citing)
BOY	0	BOY
EOY	0	EOY

Total Net Assets Fund Balances TotalNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	21588174	BOY
EOY	21121845	EOY

Total Liab Net Assets Fund Balances TotalLiabNetAssetsFundBalances

Field	Value	IRS element (for citing)
BOY	78224899	BOY
EOY	95542240	EOY

Field	Value	IRS element (for citing)
Info In Schedule O Part XI	X	InfoInScheduleOPartXI
Reconcilation Revenue Expenses	-455608	ReconcilationRevenueExpenses
Reconcilation Other Changes	-10721	ReconcilationOtherChanges
Method Of Accounting Accrual	X	MethodOfAccountingAccrual
Accountant Compile Or Review	false	AccountantCompileOrReview
FS Audited	true	FSAudited
Audit Committee	true	AuditCommittee
Financial Statement Consolidated	X	FinancialStatementConsolidated
Federal Grant Audit Required	false	FederalGrantAuditRequired

Schedule A IRS990ScheduleA

Field	Value	IRS element (for citing)
Publicly Supported Org170b1 Avi	X	PubliclySupportedOrg170b1Avi

Gifts Grants Contrib Received170 GiftsGrantsContribReceived170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	37700456	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	42077867	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	51259577	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	57125384	CurrentTaxYearMinus1Year
Current Tax Year	64970818	CurrentTaxYear
Total	253134102	Total

Total170 Total170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	37700456	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	42077867	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	51259577	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	57125384	CurrentTaxYearMinus1Year
Current Tax Year	64970818	CurrentTaxYear
Total	253134102	Total

Field	Value	IRS element (for citing)
Amounts Subst Contributors Total	102332670	AmountsSubstContributorsTotal
Public Support Total170	150801432	PublicSupportTotal170

Gross Investment Income170 GrossInvestmentIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	764390	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	744930	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	157415	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	232554	CurrentTaxYearMinus1Year
Current Tax Year	42326	CurrentTaxYear
Total	1941615	Total

Other Income170 OtherIncome170

Field	Value	IRS element (for citing)
Current Tax Year Minus4 Years	117	CurrentTaxYearMinus4Years
Current Tax Year Minus3 Years	25682	CurrentTaxYearMinus3Years
Current Tax Year Minus2 Years	15213	CurrentTaxYearMinus2Years
Current Tax Year Minus1 Year	34177	CurrentTaxYearMinus1Year
Current Tax Year	38514	CurrentTaxYear
Total	113703	Total

Field	Value	IRS element (for citing)
Total Support	255189420	TotalSupport
Public Support Pertcentage170	0.59094	PublicSupportPertcentage170
Public Support Pertcent Prior Year	0.64806	PublicSupportPertcentPriorYear
Thirty Three Percnt Tests CY170	X	ThirtyThreePercntTestsCY170

Schedule B IRS990ScheduleB

Contributor Info ContributorInfo

Field	Value	IRS element (for citing)
Contributor Number	RESTRICTED	ContributorNumber

Contributor Name Business ContributorNameBusiness

Field	Value	IRS element (for citing)
Business Name Line1	RESTRICTED	BusinessNameLine1

Contributor Address US ContributorAddressUS

Field	Value	IRS element (for citing)
Address Line1	RESTRICTED	AddressLine1
Address Line2	RESTRICTED	AddressLine2
City	RESTRICTED	City
State	RESTRICTED	State
ZIP Code	RESTRICTED	ZIPCode

Field	Value	IRS element (for citing)
Aggregate Contributions	RESTRICTED	AggregateContributions

Schedule D IRS990ScheduleD

Field	Value	IRS element (for citing)
Art Public Exhibition Amts		ArtPublicExhibitionAmts
Held Works Of Art Amts		HeldWorksOfArtAmts
Current Year Minus3 Years		CurrentYearMinus3Years
Land		Land
Buildings		Buildings

Leasehold Improvements LeaseholdImprovements

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	304571	OtherCostOrOtherBasis
Depreciation	125064	Depreciation
Book Value	179507	BookValue

Equipment Equipment

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	948147	OtherCostOrOtherBasis
Depreciation	712601	Depreciation
Book Value	235546	BookValue

Other Land Buildings OtherLandBuildings

Field	Value	IRS element (for citing)
Other Cost Or Other Basis	420284	OtherCostOrOtherBasis
Depreciation	181914	Depreciation
Book Value	238370	BookValue

Field	Value	IRS element (for citing)
Total Of Book Value Land Buildings	653423	TotalOfBookValueLandBuildings
Federal Income Tax Liability	0	FederalIncomeTaxLiability

Other Liabilities OtherLiabilities (3 entries)

DescriptionDescription	AmountAmount
DEFERRED RENT	$433,507
DUE TO MJFF CANADA	$93,270
INTEREST PAYABLE	$158,975

Field	Value	IRS element (for citing)
Total Of Amounts	685752	TotalOfAmounts
Total Revenue	65183373	TotalRevenue
Total Expenses	65638981	TotalExpenses
Excess Or Deficit For Year	-455608	ExcessOrDeficitForYear
Net Unrealized GL On Investments	-10721	NetUnrealizedGLOnInvestments
Total Adjustments	-10721	TotalAdjustments
Excess Or Deficit Per FS	-466329	ExcessOrDeficitPerFS
Tot Revenue Etc Audited Fincl Stmt	67450452	TotRevenueEtcAuditedFinclStmt
Net Unrealized Gains Investments	-10721	NetUnrealizedGainsInvestments
Other Revenues	2277800	OtherRevenues
Revenue Not Rptd F990	2267079	RevenueNotRptdF990
Revenue Subtotal	65183373	RevenueSubtotal
Total Revenue Per Form990	65183373	TotalRevenuePerForm990
Tot Expenses Etc Audited Fincl Stmt	67916781	TotExpensesEtcAuditedFinclStmt
Other Expenses Included	2277800	OtherExpensesIncluded
Expenses Not Rptd F990	2277800	ExpensesNotRptdF990
Expenses Subtotal	65638981	ExpensesSubtotal
Total Expenses Per Form990	65638981	TotalExpensesPerForm990

Form990 Schedule D Part XIV Form990ScheduleDPartXIV (2 entries)

IdentifierIdentifier	Return ReferenceReturnReference	ExplanationExplanation
Scheduel D, Page 3, Question 2:	ASC 740-10-05 Footnote	The Foundation is subject to the provisions of the Financial Accounting Standards Board's Accounting Standards Codification ("ASC") 740-10-05 relating to accounting and reporting for uncertainty in income taxes. For the Foundation, ASC 740-10-05 is potentially applicable to the incurrence of unrelated business income ("UBIT") attributable to certain of the Foundation's merchandise sales. Nonetheless, because of Foundation's general tax-exempt status, ASC 740-10-05 has not had, and is not expected to have, a material impact on the Foundation's financial statements.
RECONCILIATION OF REVENUE AND EXPENSES	SCHEDULE D, PARTS XII/XIII, LINES 2D, PAGE 4	AMOUNTS REPRESENT REVENUES AND EXPENSES ATTRIBUTABLE TO THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH'S CANADIAN ENTITY.

Schedule F IRS990ScheduleF

Field	Value	IRS element (for citing)
Grant Records Maintained	true	GrantRecordsMaintained

Accts Actvs Out US Table AcctsActvsOutUSTable (5 entries)

RegionRegion	Number Of OfficesNumberOfOffices	Number Of EmployeesNumberOfEmployees	Type Of Activities ConductedTypeOfActivitiesConducted	Total ExpendituresTotalExpenditures
East Asia and the Pacific	0	0	Grantmaking	425719
Europe (Including Iceland and Greenland)	0	0	Grantmaking	13895918
Middle East and North Africa	0	0	Grantmaking	1552620
North America	0	0	Grantmaking	1095961
North America	1	1	Maintaining offices	15280

Field	Value	IRS element (for citing)
Subtotal Number Of Offices	1	SubtotalNumberOfOffices
Subtotal Number Of Employees	1	SubtotalNumberOfEmployees
Total Number Of Offices	1	TotalNumberOfOffices
Total Number Of Employees	1	TotalNumberOfEmployees
Subtotal Amount Spent	16985498	SubtotalAmountSpent
Total Amount Spent	16985498	TotalAmountSpent

Grants To Orgs Outside US GrantsToOrgsOutsideUS (84 entries)

RegionRegion	Purpose Of GrantPurposeOfGrant	Amount Of Cash GrantAmountOfCashGrant
Europe/Iceland/Greenland	First-in-humans/patients clinical trial to assess the safety/tolerability as well as the immunogenicity and clinical activity of PD01, the first alpha-synuclein-based AFFITOPE Parkinson vaccine	1431450
Europe/Iceland/Greenland	Xenon inhalation to reduce L-Dopa-induced dyskinesia immunogenicity and clinical activity of PD01, the first alpha-synuclein-based AFFITOPE Parkinson vaccine	125004
North America	Proof of Concept of Treatment with Novel Hydroxypyridinone Iron Chelators in a Non- Clinical Model of Parkinson's Disease	412582
Middle East/North Africa	Developing a biomarker for the detection of alpha-synuclein in Parkinson's Disease Clinical Model of Parkinson's Disease	119143
Europe/Iceland/Greenland	Small molecule screening for a-synuclein binders using Surface Plasmon Resonance (SPR). Fluorescence and radiometric competition binding assays for identification of compounds selectively binding to a-synuclein	50000
Europe/Iceland/Greenland	Small molecule screening for a-synuclein binders using Surface Plasmon Resonance (SPR). Fluorescence and radiometric competition binding assays for identification of compounds selectively binding to a-synuclein	829120
Europe/Iceland/Greenland	LRRK2 Cohort Consortium- Biorespository Agreement using Surface Plasmon Resonance (SPR). Fluorescence and radiometric competition binding assays for identification of compounds selectively binding to a-synuclein	453856
Europe/Iceland/Greenland	LRRK2 role on auto-antibody production by human B cells	141717
Europe/Iceland/Greenland	The role of LRRK2 in regulating a calcium- dependent pathway involving lysosomal stores and NAADP	125000
Europe/Iceland/Greenland	Impact of LRRK2 kinase activity on synaptic v vesicle trafficking and NAADP	150000
Europe/Iceland/Greenland	Investigation of the pathogenic significance of the hyperpolarization-activated current (lh) in the degeneration of substantia nigra pars compacta dopaminergic neurons.	66660
Europe/Iceland/Greenland	Lead optimization and pharmacological characterization of selective mGluR3 PAMs as novel neuroprotective agents for Parkinson's Disease pars compacta dopaminergic neurons.	299991
Europe/Iceland/Greenland	Generation of synthetic alpha-synuclein for the PD research community neuroprotective agents for Parkinson's Disease	199626
Europe/Iceland/Greenland	Evaluation of ATP13A2 as a Molecular Target f or Ameliorating Alpha-Synuclein-Induced Neuro degeneration in Pre-Clinical Models of PD	246250
Europe/Iceland/Greenland	Evaluating novel small molecule inhibitors of LRRK2 to deliver PET Ligands degeneration in Pre-Clinical Models of PD	260000
Europe/Iceland/Greenland	NeuroEPIC Parkinson's disease study-supplement LRRK2 to deliver PET Ligands	30000
Europe/Iceland/Greenland	PPMI Clinical Trial Site - SWEDD Amendment	55688
Europe/Iceland/Greenland	The role of serotonergic and dopaminergic mechanisms and their interaction in L-DOPA induced dyskinesias	400049
Europe/Iceland/Greenland	Analysis of adhesion and chemotactic factor expression possibly involved in T cell brain extravasation in Parkinson's disease: a human postmortem analysis.	93005
Europe/Iceland/Greenland	Analysis of the ENS using routine colonic biopsies as a biomarker for PD: optimizing detecti of alpha-synuclein pathology and assessment in LRRK2 patients - SUPPLEMENT	121769
Europe/Iceland/Greenland	Identifying Markers of PD Onset and Progression in a Prospective Cohort of Patients and Asymptomatic Carriers of LRRK2 Mutations in LRRK2 patients - SUPPLEMENT	527242
Europe/Iceland/Greenland	Caspase-8 control microglia activation and neurotoxicity in Parkinson's disease Asymptomatic Carriers of LRRK2 Mutations	189078
Europe/Iceland/Greenland	Functional characterization of ATP13A2, a P-type transport ATPase involved in neurodegeneration	74993
Europe/Iceland/Greenland	Generation of LRRK2 Lentiviral Vectors transport ATPase involved in neurodegeneration	90504
Europe/Iceland/Greenland	Identification of the LRRK2 phosphatase	143375
Europe/Iceland/Greenland	Cognitive phenotypes in Parkinson's disease: anatomical and functional correlates	98266
Europe/Iceland/Greenland	In vivo validation of the AAV-alpha-synuclein vectors generated by UNC for distribution to MJFF supported research community - Kirik	52330
Europe/Iceland/Greenland	Regulated GDNF gene therapy- a novel regulatory system based on protein degradation. MJFF supported research community - Kirik	74805
Europe/Iceland/Greenland	Fractalkine-CX3Cr1 signaling in models of Parkinson disease: Quest for novel therapeutic strategies	74972
Europe/Iceland/Greenland	Axonopathy induced by overexpression of human -synuclein in the rat nigrostriatal dopamin e system	75020
Europe/Iceland/Greenland	2011 Pritzker Prize - winner -synuclein in the rat nigrostriatal dopamin e system	100000
Europe/Iceland/Greenland	TFEB and its associated microRNA-128 as targets for neuroprotection and disease intervention in Parkinson?s disease	250000
Europe/Iceland/Greenland	LRRK2 Target Engagement Ligand for neuroprotection and disease intervention in Parkinson?s disease	297000
Europe/Iceland/Greenland	Assessing and diagnosing anxiety in patients with Parkinson's disease - SUPPLEMENT	431158
Europe/Iceland/Greenland	Implementation of PD GWAS meta-analysis results on the PDGene database.	11303
Europe/Iceland/Greenland	LRRK2 GTPase validation and inhibitor discovery on the PDGene database.	182068
Europe/Iceland/Greenland	Activation of GPR88 by a small molecular weight compound: screening for drug-like modulators of GPR88 function.	75000
Europe/Iceland/Greenland	Preclinical Development of Encapsulated Cell Biodelivery of GDNF for Parkinson's Disease of GPR88 function.	681941
East Asia/Pacific	Generation of VPS35 mutant mouse model - MJFF -Elan Partnership-1373 Liffey- Original PI Beales	64500
Europe/Iceland/Greenland	PPMI Clinical Trial Site - SWEDD Amendment -Elan Partnership-1373 Liffey- Original PI Beales	59438
Europe/Iceland/Greenland	Ghrelin concentrations in CSF and corresponding serum samples in PD patients and controls	84063
East Asia/Pacific	PBT434, a novel neuroprotective drug for Parkinson's disease:completion of preclinical studies to enable human clinical trials.	206110
Europe/Iceland/Greenland	Clinical Coordination of LRRK2 Cohort Consortium Parkinson's disease:completion of preclinical studies to enable human clinical trials.	73895
Europe/Iceland/Greenland	Dopamine D1 Positive Modulators for the Treatment of Parkinson's disease	151444
Europe/Iceland/Greenland	Assessing the therapeutic potential of iDA neuronal cells in autologous strategy	75000
Europe/Iceland/Greenland	Pharmacological testing of Nurr1 agonists in animal models of Parkinson's Disease	540656
Europe/Iceland/Greenland	Next Generation Parkinson's Disease Treatment through Steering Brain Stimulation (NEXT)	366717
Middle East/North Africa	Validation of Skp1 as a new target for PD therapy through Steering Brain Stimulation (NEXT)	238000
Middle East/North Africa	fMRI of first degree relatives of LRRK2 positive PD patients	199000
Middle East/North Africa	Autonomic dysfunction in LRRK2 mutation carriers: Characterization of autonomic profiles of patients with PD, carriers of mutations in the LRRK2 gene and non-manifesting first degree relatives.	249543
Middle East/North Africa	Gait and motor symptoms in healthy asymptomatic relatives of Patients with PD carriers of mutations in the LRRK2 gene the LRRK2 gene and non-manifesting first degree relatives.	496174
Europe/Iceland/Greenland	Targeting dramatically activated astrocytic networks for managing LID: a target validation program	140500
Europe/Iceland/Greenland	New roles for the Parkinson's disease kinase LRRK2 in cytoskeletal dynamics program	100025
Europe/Iceland/Greenland	Investigating signaling pathway dysfunction linked to LRRK2	249378
Middle East/North Africa	Testing novel compounds for noninvasive delivery of small interfering RNA into CNS	74979
Middle East/North Africa	Validation of alpha-synuclein oligomers as biomarker for Parkinson?s disease	175783
Europe/Iceland/Greenland	Characterization of LRRK1 and LRRK2 interaction partners	200000
Europe/Iceland/Greenland	Alpha-Synuclein Assay - Competitive Binding Study partners	18508
Europe/Iceland/Greenland	Generation of alpha-synuclein filament protein and characterization of alpha-synuclein rabbit monoclonal antibodies	73700
Europe/Iceland/Greenland	Regulatory T cells as modulators of microglia's inflammatory response rabbit monoclonal antibodies	200000
North America	2011 Pritzker Prize - runner up inflammatory response	10000
North America	Multi-tracer positron emission tomography (PET) functional imaging as a tool to assess the relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism	252874
Europe/Iceland/Greenland	Targeting of alpha-synuclein and SNARE complex dysfunction to restore synaptic dopamine release in a model of Parkinson disease pathology. neurochemical phenotype associated with LRRK2 mutations related Parkinsonism	75000
Europe/Iceland/Greenland	Analysis of a viral non-coding RNA as a novel therapeutic in a chronic MPTP mouse model of Parkinson's disease and its mechanism of mitochondrial protection	149999
Europe/Iceland/Greenland	ABILITY OF A MITOCHONDRIA IMPROVER, BERBERINE, TO ATTENUATE PARKINSON'S DISEASE Parkinson's disease and its mechanism of mitochondrial protection	57354
Europe/Iceland/Greenland	Generation of LRRK1 protein and characterization of LRRK1 mouse and rabbit monoclonal antibodies.	14735
Europe/Iceland/Greenland	Analysis of LRRK2 antibodies of LRRK1 mouse and rabbit monoclonal antibodies.	93531
Europe/Iceland/Greenland	Determine the structure of Roco family proteins	249969
Europe/Iceland/Greenland	Novel Neuroprotective Cell-Penetrating Peptides	74580
Europe/Iceland/Greenland	CDNF (Cerebral Dopamine Neurotrophic Factor) for therapy of Parkinson's disease	180225
Europe/Iceland/Greenland	CDNF (Cerebral Dopamine Neurotrophic Factor) for therapy of Parkinson's disease	188819
Europe/Iceland/Greenland	PPMI Clinical Trial Site - SWEDD Amendment for therapy of Parkinson's disease	59438
North America	The Nur77/RXR transcriptional complex as a new target in L-Dopa-induced dyskinesia treatment	100056
East Asia/Pacific	LRRK2 physiology in Parkinson's disease target in L-Dopa-induced dyskinesia treatment	74103
Europe/Iceland/Greenland	Predicting cognitive profiles in Parkinson's disease: A multimodal approach	153341
Europe/Iceland/Greenland	Clinical Trial to Compare Cognitive Scales disease: A multimodal approach	1480549
East Asia/Pacific	C-type Natriuretic Peptide (CNP): a putative biomarker of neuronal damage in Parkinsons Disease	81006
Europe/Iceland/Greenland	Validation of lysosomal enzymes assay in CSF - One-year extension of the RRIA: CSF lysosomal hydrolases' activity as possible marker of Parkinson's disease	100000
North America	The relationship between cognitive phenotypes of PD with visual hallucinations and 5HT2A receptors in the inferotemporal cortex. Parkinson's disease	245509
Europe/Iceland/Greenland	PPMI Additional Insurance for DaTscan of PD with visual hallucinations and 5HT2A receptors in the inferotemporal cortex.	14112
Europe/Iceland/Greenland	PPMI Clinical Trial Site - SWEDD Amendment	59438
Europe/Iceland/Greenland	2011 - Pritzker Prize - runner up	10000
North America	Developing a Human Neural Model for Parkinson's Disease	74941
Europe/Iceland/Greenland	Evaluation of LRRK2-derived Bioportides as Functional Protein Modulators and Potential Therapeutics	93269

Field	Value	IRS element (for citing)
Total Number Of501c3 Orgs	46	TotalNumberOf501c3Orgs
Total Number Of Other Orgs	15	TotalNumberOfOtherOrgs
Transfer To Foreign Corp	false	TransferToForeignCorp
Interest In Foreign Trust	false	InterestInForeignTrust
Own Foreign Corp	false	OwnForeignCorp
Passive Foreign Invest Co	false	PassiveForeignInvestCo
Foreign Partnership	false	ForeignPartnership
Boycott Countries	false	BoycottCountries

Form990 Schedule F Part V Form990ScheduleFPartV

Field	Value	IRS element (for citing)
Identifier	SCHEDULE F	Identifier
Return Reference	PROCEDURES FOR MONITORING GRANT FUNDS OUTSIDE THE UNITED STATES:	ReturnReference
Explanation	THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THE SCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.	Explanation

Schedule G IRS990ScheduleG

Field	Value	IRS element (for citing)
Mail Solicitations	X	MailSolicitations
Email Solicitations	X	EmailSolicitations
Solicitation Of Non Govt Grants	X	SolicitationOfNonGovtGrants
Special Fundraising Events	X	SpecialFundraisingEvents
Agreement Ref Fundraising	true	AgreementRefFundraising

Fundraiser Activity Information FundraiserActivityInformation

Field	Value	IRS element (for citing)
Name Of Individual	Event Associates Inc	NameOfIndividual
Activity	Fundraising Consultants	Activity
Fundraiser Control Of Funds	false	FundraiserControlOfFunds
Gross Receipts	0	GrossReceipts
Amount Retained By Contractor	60000	AmountRetainedByContractor
Net To Organization	0	NetToOrganization

Field	Value	IRS element (for citing)
Total Gross Receipts	0	TotalGrossReceipts
Total Retained By Contractors	60000	TotalRetainedByContractors
Total Net To Organization	0	TotalNetToOrganization
Licensed States	AL	LicensedStates
Licensed States	AK	LicensedStates
Licensed States	AZ	LicensedStates
Licensed States	AR	LicensedStates
Licensed States	CA	LicensedStates
Licensed States	CO	LicensedStates
Licensed States	CT	LicensedStates
Licensed States	FL	LicensedStates
Licensed States	GA	LicensedStates
Licensed States	IL	LicensedStates
Licensed States	KS	LicensedStates
Licensed States	KY	LicensedStates
Licensed States	ME	LicensedStates
Licensed States	MD	LicensedStates
Licensed States	MA	LicensedStates
Licensed States	MI	LicensedStates
Licensed States	MN	LicensedStates
Licensed States	MS	LicensedStates
Licensed States	NH	LicensedStates
Licensed States	NJ	LicensedStates
Licensed States	NM	LicensedStates
Licensed States	NY	LicensedStates
Licensed States	NC	LicensedStates
Licensed States	ND	LicensedStates
Licensed States	OH	LicensedStates
Licensed States	OK	LicensedStates
Licensed States	OR	LicensedStates
Licensed States	PA	LicensedStates
Licensed States	RI	LicensedStates
Licensed States	SC	LicensedStates
Licensed States	TN	LicensedStates
Licensed States	UT	LicensedStates
Licensed States	VA	LicensedStates
Licensed States	WA	LicensedStates
Licensed States	WV	LicensedStates
Licensed States	WI	LicensedStates

Events Information EventsInformation

Field	Value	IRS element (for citing)
Name Of Event1	FUNNY THING	NameOfEvent1
Gross Receipts Event1	4326808	GrossReceiptsEvent1
Charitable Contributions Event1	3667648	CharitableContributionsEvent1
Gross Revenue Event1	659160	GrossRevenueEvent1
Rent Facility Costs Event1	390310	RentFacilityCostsEvent1
Entertainment Event1	239525	EntertainmentEvent1
Other Direct Expenses Event1	29324	OtherDirectExpensesEvent1
Name Of Event2	BREAKING PAR	NameOfEvent2
Gross Receipts Event2	654319	GrossReceiptsEvent2
Charitable Contributions Event2	593631	CharitableContributionsEvent2
Gross Revenue Event2	60688	GrossRevenueEvent2
Rent Facility Costs Event2	40079	RentFacilityCostsEvent2
Food And Beverage Event2	17835	FoodAndBeverageEvent2
Entertainment Event2	2000	EntertainmentEvent2
Other Direct Expenses Event2	775	OtherDirectExpensesEvent2
Total Number Of Other Events	1	TotalNumberOfOtherEvents
Gross Receipts Other Events	465613	GrossReceiptsOtherEvents
Charitable Contrib Other Events	389977	CharitableContribOtherEvents
Gross Revenue Other Events	75636	GrossRevenueOtherEvents
Non Cash Prizes Other Events	29077	NonCashPrizesOtherEvents
Rent Facility Costs Other Events	27650	RentFacilityCostsOtherEvents
Entertainment Other Events	14900	EntertainmentOtherEvents
Other Direct Expenses Other Events	4009	OtherDirectExpensesOtherEvents
Gross Receipts Total	5446740	GrossReceiptsTotal
Charitable Contributions Total	4651256	CharitableContributionsTotal
Gross Revenue Total Events	795484	GrossRevenueTotalEvents
Non Cash Prizes Total Events	29077	NonCashPrizesTotalEvents
Rent Facility Costs Total Events	458039	RentFacilityCostsTotalEvents
Food And Beverage Total Events	17835	FoodAndBeverageTotalEvents
Entertainment Total Events	256425	EntertainmentTotalEvents
Other Direct Expenses Total Events	34108	OtherDirectExpensesTotalEvents
Direct Expense Summary Events	795484	DirectExpenseSummaryEvents

Schedule I IRS990ScheduleI

Field	Value	IRS element (for citing)
Records Maintained	true	RecordsMaintained

Recipient Table RecipientTable (213 entries)

Address Line1AddressUS/AddressLine1	CityAddressUS/City	StateAddressUS/State	ZIP CodeAddressUS/ZIPCode	EIN Of RecipientEINOfRecipient	IRC SectionIRCSection	Amount Of Cash GrantAmountOfCashGrant	Purpose Of GrantPurposeOfGrant
Allen Institute for Brain Science
551 N 34th Street	Seattle	WA	98103	912155317	501(c)(3)	10000	Characterization Study -Allen Institute Scanning Slides
Allen Institute for Brain Science
551 N 34th Street	Seattle	WA	98103	912155317	501(c)(3)	20000	Characterization Study -Allen Institute Scanning Slides - LRRK2 Disease
Aperio Technologies
1360 Park Center Drive	Vista	CA	92081	330939292	Public Sector	6840	Aperio Technologies Slide Hosting Scanning Slides - LRRK2
Aperio Technologies
1360 Park Center Drive	Vista	CA	92081	330939292	Public Sector	15960	Aperio Technologies Slide Hosting - LRRK2 chaperone AT3375 to reduce alpha-synuclein levels in the brain of Thy-1 alpha-synuclein mice
Avid Radiopharmaceuticals Inc
4435 North First St Suite 360	Livermore	PA	94551	201811104	Public Sector	664531	Developing an a-synuclein imaging agent therapeutics for PD
Banner Health Institute
10515 West Santa Fe Drive	Sun City	AZ	85351	860768795	501(c)(3)	168214	Identifying peripheral inflammatory markers for Parkinson's disease with dementia (PDD)
Banner Sun Health Research Institute
10516 West Santa Fe Drive	Sun City	AZ	85351	860768795	501(c)(3)	55688	PPMI Clinical Trial Site - SWEDD Amendment for Parkinson's disease with dementia (PDD)
Banner Sun Health Research Institute
10515 W Santa Fe Drive	Sun City	AZ	85351	860768795	501(c)(3)	63971	LRRK2 Antibody Testing in Postmortem Human Brain Cell Product for Treatment of Parkinson's Disease
Banner Sun Health Research Institute
10515 West Santa Fe Drive	Sun City	AZ	85351	860768795	501(c)(3)	102304	Characterization of inflammatory mediators during early stages of Parkinson's disease
Baylor College of Medicine
6550 Fannin Suite 1801	Houston	TX	77030	741613878	501(c)(3)	59438	PPMI Clinical Trial Site - SWEDD Amendment during early stages of Parkinson's disease
Baylor College of Medicine
6501 Fannin St NB 205	Houston	TX	77030	741613878	501(c)(3)	74800	Alpha-synuclein May Be Responsible for the Link Between Parkinson's Disease and Melanoma
Baylor College of Medicine
6550 Fannin Suite 1801	Houston	TX	77030	741613878	501(c)(3)	333750	PPMI Clinical Trial Site: Year Two Between Parkinson's Disease and Melanoma
Beth Israel Medical Center
Suite 5J 10 Union Square East	New York	NY	10003	135564934	501(c)(3)	104473	Analytic Models in Biomarker Development
Beth Israel Medical Center
10 Union Square East Suite 2Q	New York	NY	10003	135564934	501(c)(3)	4717696	The Parkinson's Disease, Ashkenazi Jews and LRRK2 Consortium - a longitudinal extension
Biomer Technology
1047 Serpentine Lane Bldg 200	Pleastown	CA	94566	481286101	Public Sector	6865	Generation of LRRK2 phospho-peptides LRRK2 Consortium - a longitudinal extension
Boston University
Robinson C-329 715 Albany St	Boston	MA	02118	042103545	501(c)(3)	55688	PPMI Clinical Trial Site - SWEDD Amendment
Boston University
72 E Concord Street	Boston	MA	02118	042103545	501(c)(3)	199605	Role of Gad1 in l-DOPA-induced dyskinesias molecule inhibitors of cytosolic Hsp90
Brandeis University
415 South Street MS029	Waltham	MA	024549110	042103552	501(c)(3)	73177	Caspase- 1 Inhibition to reduce cleaved alpha synuclein in rodent models of Parkinson's disease
Brigham & Women's Hospital
65 Landsdowne Street Suite 301A	Cambridge	MA	02139	042312909	501(c)(3)	74968	Unlimited discovery of non-coding, regulatory RNAs and aberrant splicing in Parkinson's
California Institute of Technology
1200 E California Blvd Division of	Pasadena	CA	91125	956006144	501(c)(3)	150000	Mouse Strains for Specifying Nicotinic Receptor Targets in Parkinson's Disease Neuroprotecion
Ceregene Inc
9381 Judicial Drive Suite 130	San Diego	CA	92121	954838818	Public Sector	1000000	A Sham- Surgery Controlled Phase 2 Trial Testing AAV2-neurturin (CERE-120) in Moderately Advanced Parkinson Disease of PD
Chaperone Therapeutics Inc
Six Davis Drive	Triangle Park	NC	27709	263584962	Public Sector	149044	Development of Hsf1 effectors as Parkinson's disease therapeutics Advanced Parkinson Disease of PD-Supplement
Civitas
190 Everett Ave	Chelsea	MA	02150	271482814	Public Sector	312665	A Novel, Validated, Dry Powder-Based Delivery of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease Patients
Cleveland Clinic
9500 Euclid Avenue S-31	Cleveland	OH	44195	340714585	501(c)(3)	59438	PPMI Clinical Trial Site - SWEDD Amendment of Intrapulmonary Levodopa as a Treatment for Motor Fluctuations in Parkinson's Disease Patients
Cleveland Clinic
9500 Euclid Avenue S-31	Cleveland	OH	44195	340714585	501(c)(3)	257031	PPMI Clinical Trial Site
Colorado State University
1680 Campus Delivery	Fort Collins	CO	805231680	846000545	501(c)(3)	103993	Targeting glia in PD with novel anti- inflammatorry therapeutics
Columbia University
701 W168th Street	New York	NY	10032	135598093	501(c)(3)	74998	DIRECT REPROGRAMMING OF CELLS INTO DOPAMINE NEURONS
Columbia University
650 West 168th Street BB 306	New York	NY	10032	135598093	501(c)(3)	74999	Assessment of AAV Transduction with Wildtype and Constitutively Active p70S6K to Induce Axon Re-Growth in Dopamine Neurons
Columbia University
650 W 168th St Black Building Roo	New York	NY	10032	135598093	501(c)(3)	75000	Glyt1 inhibitors promote dopaminergic striatal sprouting Axon Re-Growth in Dopamine Neurons
Columbia University
710 W168th St 3rd floor	New York	NY	10032	135598093	501(c)(3)	251538	Neuropathological tissue collection in G2019S carriers with and without PD
Coriell Institute for Medical Research
403 Haddon Avenue	Camden	NJ	081030000	210672684	501(c)(3)	16182	LRRK2 Cohort/PPMI Shipping Validation Study carriers with and without PD
Coriell Institute for Medical Research
403 Haddon Avenue	Camden	NJ	081030000	210672684	501(c)(3)	330916	LRRK2 Cohort Consortium: Coriell Biorepository Tolerability, Pharmacokinetics and Pharmacodynamics following Administration of Gastric Retentive Extended-Release Tablets versus a Reference Extended-Release Tablet in Parkinson's Disease Patients
Coriell Institute for Medical Research
403 Haddon Avenue	Camden	NJ	081030000	210672684	501(c)(3)	827468	LRRK2 Cohort Consortium: Longitudinal Efforts Biorepository Agreement Therapy in 6-OHDA Non-human Primates
Covance
180 Rustcraft Road	Dedham	IN	020260000	223265977	Public Sector	10000	Analysis of DJ-1 levels in fifteen of PPMI qualification study CSF samples
Covance
180 Rustcraft Road	Dedham	IN	020260000	223265977	Public Sector	10700	Alpha-Synuclein Secretion Work qualification study CSF samples
Covance
180 Rustcraft Road	Dedham	IN	020260000	223265977	Public Sector	40920	Measurement of Abeta species in Parexel Quali Qualification Study
Covance
180 Rustcraft Road	Dedham	IN	020260000	223265977	Public Sector	65615	Analysis of biomarkers in CSF samples from PD and elderly populations
Covance
180 Rustcraft Road	Dedham	IN	020260000	223265977	Public Sector	120000	PPMI 2011: Hemoglobin Analyses (April 2011) and elderly populations
Durin Technologies Inc
2 Medical Center Drive Rm 313	Stratford	NJ	080840000	272247948	Public Sector	367083	Identification and validation of blood-borne autoantibody biomarkers for detection, diagnosis and staging of Parkinson's disease
Emory University
615 Michael Street	Atlanta	GA	303223110	580566256	501(c)(3)	6250	Characterization of inflammatory mediators during early stages of Parkinson's disease and staging of Parkinson's disease
Emory University
615 Michael Street	Atlanta	GA	303223110	580566256	501(c)(3)	25000	Estimating neuroprotective effects of nigral AAV-NRTN using selective reaction monitoring to quantitatively measure p-erk1/2 signaling strength in nigral DA neurons
Emory University
1841 Clifton Road Third Floor	Atlanta	GA	30329	580566256	501(c)(3)	59438	PPMI Clinical Trial Site - SWEDD Amendment AAV-NRTN using selective reaction monitoring to quantitatively measure p-erk1/2 signaling strength in nigral DA neurons
Emory University
615 Michael Street	Atlanta	GA	30324	580566256	501(c)(3)	75000	Psychological Stress as a Risk Factor for Prarkinson's Disease
Emory University
1599 Clifton Road 4th	Atlanta	GA	30322	580566256	501(c)(3)	200000	Role of PARK18 in Parkinson's Disease Prarkinson's Disease
Envoy Therapeutics
555 Heritage Drive	Jupiter	FL	33458	262535708	Public Sector	350000	A Novel Oral Treatment for Parkinson's Disease Based on Highly Specific Modulation of the Indirect Pathway.
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	5029	Additional Generation of Monoclonal LRRK2 Antibody -- LRRK2 MJFF-2 (clone c41-2) Indirect Pathway.
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	15026	Generation of Monoclonal and Polyclonal Antib Antodies against Aggregated Forms of Alpha- Synuclein
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	15212	Batch Antibody Production for Alessi Rabbit M Monoclonal LRRK2 Antibodies Synuclein
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	15306	Generation of Monoclonal and Polyclonal Antibodies against LRRK1
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	15709	Monoclonal Antibody Generation against Oxidized DJ-1
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	27858	Alpha-Synuclein Phospho-specific Polyclonal and Monoclonal Antibody Generation
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	55496	LRRK2 Phospho-specific Polyclonal and Monoclonal Antibody Generation
Epitomics
863 Mitten Road Suite 103	Burlingame	CA	94010	943409030	Public Sector	58686	Additional LRRK2 Antibody Services: Phase VI-VIII Monoclonal Antibody Generation
ExSAR
11 Deer Park Drive Suite 103	Monmouth Junction	NJ	08852	134000553	Public Sector	430059	Testing of ambroxol in the Thy1-alphaSyn mouse model of Parkinson's disease disease
GeneGo
500 Renaissance Drive 106	St Joeseph	MI	49085	231569117	Public Sector	49093	GeneGo LRRK2 Pathway Map - Laura Brovold (Gene Go/Thomson Reuters)
Gradient Biomodeling LLC
8040 Juniper Drive	Park City	UT	84098	264634309	Public Sector	200000	Identification of Nrf2 activators using an in silico modeling platform, followed by evaluation of these compounds in an alpha-synuclein model of PD
Harvard University
243 Charles St	Cambridge	MA	021150000	421035800	501(c)(3)	40000	Blood-Brain Barrier Modification Using Heterotopic Nasal Mucosal Grafting for Enhanced Symptomatic and Macromolecular Disease Modifying Drug Delivery in Parkinson's Disease
Harvard University
25 Shattuck St	Boston	MA	021150000	421035800	501(c)(3)	75000	Defining PARKIN substrates through systematic quantitative proteomics Symptomatic and Macromolecular Disease Modifying Drug Delivery in Parkinson's Disease
Harvard University
65 Landsdowne Street Suite 301A	Cambridge	MA	021390000	421035800	501(c)(3)	150000	Alpha-synuclein expression lowering therapeutics: Hit confirmation
Harvard University
115 Mill Street	Belmont	MA	024780000	421035800	501(c)(3)	225000	Duloxetine hydrochloride as a novel neuroprotective treatment for Parkinson's disease
Henry Ford Health System - Henry Ford Hospital
5777 West Maple Road	West Bloomfield	MI	48322	381357020	501(c)(3)	506282	Droxidopa treatment of gait, sleep, and cognitive disorders in Parkinson's disease
Impax Laboratories Inc
31047 Genstar Rd	Hayward	CA	94544	650403311	Public Sector	400000	Testing effects of improved l-dopa delivery with dexterity and gait objective measures
Indiana University
410 West Tenth Street HS 4021 Indi	Indianapolis	IN	462023002	356001673	501(c)(3)	10020	Storage of biospecimens from MJFF biomarker study
Indiana University
410 West Tenth Street HS 4021 Indi	Indianapolis	IN	462023002	356001673	501(c)(3)	24309	Mega-Meta-Analysis and Neurochip Development study
Indiana University
410 West Tenth Street HS 4021 Indi	Indianapolis	IN	462023002	356001673	501(c)(3)	137491	Storage and Distribution of DATATOP samples
Invitrogen Corporation
501 Charmany Drive	Madison	NY	53719	330373077	Public Sector	11800	LRRK2 Biochemical Studies (Invitrogen/Nichols
Invitrogen Corporation
501 Charmany Drive	Madison	NY	53719	330373077	Public Sector	100150	Generation of Full Length LRRK2 protein by Invitrogen
Johns Hopkins University
600 N Wolfe Street Meyer 6-119B	Baltimore	MD	21287	520595110	501(c)(3)	59438	PPMI Clinical Trial Site - SWEDD Amendment Invitrogen
Lauren Sciences LLC
71 East 77th Street Suite 8A	New York	NY	10075	273076076	Public Sector	321464	Delivery of GDNF to the Brain by Novel Nanovesicles for the Treatment of PD
Lucigen Corporation
2120 W Greenview Dr Ste 9	Middleton	WI	53562	391923306	Public Sector	185416	Screening & Identification of small-molecule pharmacophores modulating LRRK2 activity
Mayo Clinic
4500 San Pablo Road	Jacksonville	FL	32224	593337028	501(c)(3)	28097	Characterization of LRRK2 monoclonal antibodies in rodent brain tissue--Melrose
Mayo Clinic
13400 E Shea Blvd	Scottsdale	AZ	85259	593337028	501(c)(3)	50000	Salivary Gland Biopsies as a Diagnostic Test for Parkinson's Disease Tolerability Study of Isradipine as a Disease Modifying Agent in Patients With Early Parkinson's Disease
McLean Hospital
115 Mill Street	Belmont	MA	02478	042697981	501(c)(3)	75000	Xenon Neuroprotection in a Rat Parkinson's Model for Parkinson's Disease efficacious approach to treating Parkinson's disease
McLean Hospital
115 Mill Street	Belmont	MA	02478	042697981	501(c)(3)	125000	Inhibition of LINGO-1 as a novel target for regeneration in preclinical PD models
Melior Discovery
860 Springdale Drive	Exton	PA	19341	202055208	Public Sector	324750	Evaluation of a Specific DAT Inhibitor in Pre- clinical Models of Parkinson's Disease
Michigan State University
33 Bostwick Ave NE	Grand Rapids	MI	49503	386005984	501(c)(3)	74999	Alpha-Synuclein Knockdown: Therapeutic or Toxic? clinical Models of Parkinson's Disease
Molecular Neuroimaging LLC
60 Temple Street 8th floor	New Haven	CT	065100000	060582206	Public Sector	588506	Development of functional imaging for CB-1 and 5-HT1a in PD participants with Dyskinesia
Mount Sinai School of Medicine
Box 1137 One Gustave L Levy Place	New York	NY	10029	136171197	501(c)(3)	49727	LRRK2 Immunocytochemistry in Cultured Neurons 5-HT1a in PD participants with Dyskinesia
Mount Sinai School of Medicine
Box 1137 One Gustave L Levy Place	New York	NY	10029	136171197	501(c)(3)	250000	Structural, post-translational modification and small chemical approaches to understand LRRK2 function in PD treatment of L-DOPA-induced dyskinesias. - Linked to Bjorklund CIA 2009
Mount Sinai School of Medicine
Box 1137 One Gustave L Levy Place	New York	NY	10029	136171197	501(c)(3)	262491	LRRK2 Effects on Neural Differentiation and small chemical approaches to understand LRRK2 function in PD
National Institute on Aging
35 Convent Drive Building 35 Room	Bethesda	MD	20892	522038294	501(c)(3)	50000	Biochemical characterization of full length human recombinant LRRK1 and LRRK2
National Institute on Drug Abuse (NIDA)NIH
251 Bayview Blvd 06A721	Baltimore	MD	21224	520858115	501(c)(3)	400000	DPP-4 inhibitors for the treatment of Parkinson's Disease
NeuroHealing Pharmaceuticals Inc
50 Undine Road Unit 1	Newton	MA	021350000	743095627	Public Sector	500000	NH004 Films for Sialorrhea in PD Patients Parkinson's Disease
Neurolixis Inc
29432 Clipper Way	Laguna Niguel	CA	92677	452236871	Public Sector	249355	Enhanced activity in rodent models of Parkinsonism and L-DOPA-induced dyskinesias by preferential targeting of subpopulations of 5-HT1A receptors.
Neurologix Inc
One Bridge Plaza Suite 695	Fort Lee	NJ	070240000	061582875	Public Sector	199815	Neurologix Gene Therapy AAV-GAD Phase 3 Product Development preferential targeting of subpopulations of 5-HT1A receptors.
NeuroPhage Pharmaceuticals
222 Third Street Suite 3120	Cambridge	MA	021420000	208558071	Public Sector	147140	Characterization of NPT001-mediated alpha- synuclein disaggregation and clearance
Neuroscience Associates
10915 Lake Ridge Drive	Knoxville	TN	379344919	621540123	Public Sector	158028	Characterization Study -NeuroScience Associates Mouse and Rat Characterization-ELAN
Neuroscience Associates
10915 Lake Ridge Drive	Knoxville	TN	379344919	621540123	Public Sector	197382	Characterization Study -NeuroScience Associates Mouse and Rat Characterization- LRRK2
New York University
145 East 32nd Street 2nd Floor	New York	NY	10016	135562308	501(c)(3)	507804	Bioanatomical Phenotype of Parkinson's disease with and without cognitive impairment
Northwestern University
710 North Lake Shore Drive 1425 Ab	Chicago	IL	60611	362167817	501(c)(3)	19233	2011 PPMI Steering Committee Grant for Tanya Simuni
Northwestern University
710 North Lake Shore Drive 1425 Ab	Chicago	IL	60611	362167817	501(c)(3)	99063	PPMI Clinical Trial Site - SWEDD Amendment Simuni
Northwestern University
303 E Chicago Ave	Chicago	IL	60611	362167817	501(c)(3)	248532	Identification of a novel calcium selective antagonist for neuroprotection in PD
ORC International
902 Carnegie Center Suite 220	Princeton	NJ	085400000	223118960	Public Sector	83800	ORC Survey Project - 2011 antagonist for neuroprotection in PD
Oregon Health & Science University
3181 SW Sam Jackson Park Rd OP-32	Portland	OR	97239	931176109	501(c)(3)	25188	PPMI 2011: TAP-PD Ancillary Study OHSU
Oregon Health & Science University
3181 SW Sam Jackson Park Rd OP-32	Portland	OR	97239	931176109	501(c)(3)	55688	PPMI Clinical Trial Site - SWEDD Amendment PD program
Oregon Health & Science University
3181 SW Sam Jackson Park Road	Portland	OR	97239	931176109	501(c)(3)	149900	Increased sensitivity to the loss of nigrostriatal dopamine following progressive MPTP treatment in LRRK2 mutant mice.
Oregon Health & Science University
3181 SW Sam Jackson Park Rd OP-32	Portland	OR	97239	931176109	501(c)(3)	333750	PPMI Clinical Trial Site: Year Two nigrostriatal dopamine following progressive MPTP treatment in LRRK2 mutant mice.
Parexel
1560 Chevy Chase Drive Suite 140	Glendale	IL	91206	043517643	Public Sector	38400	PAREXEL Protocol Development for Sanofi Trial MJFF-6/7/8/9-P3520/P3521/P3522/P3523
Parexel
1560 Chevy Chase Drive Suite 140	Glendale	IL	91206	043517643	Public Sector	672570	Collection of blood and CSF from people with Parkinson's disease over 24-36 hours
Parkinson's Action Network
1025 Vermont Ave NW Suite 1120	Washington	DC	20005	943172675	501(c)(3)	250000	PAN Funding 2011 Parkinson's disease over 24-36 hours
Parkinson's Disease and Movement Disorder Center o
951 NW 13th Street Bldg 5-E	Boca Raton	FL	33486	223659456	501(c)(3)	326969	PPMI Clinical Trial Site
Pfizer Global Research and Development
Eastern Point Road	Groton	CT	063400000	141396954	Public Sector	326000	Development of LRRK2 Target Engagement Ligands
Proteos
4717 Campus Drive	Kalamazoo	MI	49008	260069252	Public Sector	65861	PINK1 Protein Generation (Proteos) of Parkinson's disease in a rat animal model
PsychoGenics
765 Old Saw Mill River Road Suite 2	Tarrytown	NY	10591	134034631	Public Sector	350000	SmartCube Characterization Study - Characteri- zation of DJ1 and PINK1 KO Rats
Rush University
1735 W Harrison Suite 324	Chicago	IL	60612	362174823	501(c)(3)	74920	Intestinal microbiota, permeability and alpha- synclein aggregation in Parkinson's disease
Rush University
1735 West Harrison Street Suite 30	Chicago	IL	60612	362174823	501(c)(3)	74997	Nmnat function in axonal neuroprotection synclein aggregation in Parkinson's disease
Rush University
1735 West Harrison Street Suite 30	Chicago	IL	60612	362174823	501(c)(3)	124645	Gene delivery of miRNAs to reduce alpha synuclein: a new therapy for PD
Saint Jude Children's Research Hospital
332 North Lauderdale	Memphis	TN	38105	162064601	501(c)(3)	93640	GSTpi as a Blood Based Biomarker for Parkinson's Disease
SeaChange Pharmaceuticals Inc
1700 4TH ST BYERS HALL STE 214	SAN FRANCISCO	CA	941582330	270530771	Public Sector	74920	Identifying approved and investigational drugs with activity on Parkinson's disease targets
SpringBox Ltd
708 Congress Avenue Austin Texas 7	Austin	TX	78701	841643767	Public Sector	6300	Fox Trial Finder Discovery and Build Out-2011 addition- Supplement
SpringBox Ltd
708 Congress Ave	Austin	TX	78701	841643767	Public Sector	28770	Fox Trial Finder Discovery and Build Out-2011 addition
Stanford University
299 Campus Drive	Stanford	CA	94305	941156365	501(c)(3)	75000	Transport and transfer of misfolded alpha- synuclein in neurons
Stanford University
3801 Miranda Avenue Bldg100 Rm D3-	Palo Alto	CA	94306	941156365	501(c)(3)	125000	TGF-beta Signaling as Novel Therapeutic Treatment for Parkinson's Disease
Stanford University
Rm A343 300 Pasteur Drive	Stanford	CA	94305	941156365	501(c)(3)	428629	Development of multimodal imaging biomarkers for cognitive dysfunction in Parkinson's disease
State University of New York at Binghamton
4400 Vestal Parkway East Science I	Binghamton	NY	139026000	141368361	501(c)(3)	248750	Targeting Serotonin Transporters for the treatment of L-DOPA-induced Dyskinesia
State University of New York at Buffalo
124 Sherman Hall	Buffalo	NY	14214	141368361	501(c)(3)	150000	Generating Patient-Specific Induced Pluripotent Stem Cells to Study Parkinson's Disease
SynAgile Corporation
6114 LaSalle Ave 427	Oakland	CA	94611	274644283	Public Sector	699999	Continuous Subcutaneous Levodopa Prodrug Infusion
Taconic
5 Cedar Brook Drive	Cranbury	NJ	085120000	330675808	Public Sector	37931	Characterization Study -Taconic Aging of CJ Li's LRRK2 Rats
Taconic
5 Cedar Brook Drive	Cranbury	NJ	085120000	330675808	Public Sector	59000	Generation of GBA mutant mice LRRK2 Rats
Taconic
5 Cedar Brook Drive	Cranbury	NJ	085120000	330675808	Public Sector	71620	Taconic TH-GFP Rat Generation a comparison of CSF and blood
Targacept Inc
200 East First Street Suite 300	WinstonSalem	NC	271014165	562020050	Public Sector	499663	Effect of Novel Neuronal Nicotinic Receptor C Compounds on Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
The Institute for Neurodegenerative Disorders
60 Temple Street Suite 8B	New Haven	CT	065100000	061582206	501(c)(3)	10938	PPMI 2011: Leadership Core Support for 'Three Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarkers Study (TAP-PD), A PPMI Sub-study'
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	065110000	061582206	501(c)(3)	25188	PPMI 2011: TAP-PD Ancillary Study IND Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarkers Study (TAP-PD), A PPMI Sub-study'
The Institute for Neurodegenerative Disorders
60 Temple Street Suite 8B	New Haven	CT	065100000	061582206	501(c)(3)	42500	PPMI 2011: SWEDD Addendum -- Support for Leadership Core
The Institute for Neurodegenerative Disorders
60 Temple Street Suite 8B	New Haven	CT	065100000	061582206	501(c)(3)	42604	PPMI: 2011 Support for Study Call Center Leadership Core
The Institute for Neurodegenerative Disorders
60 Temple Street Suite 8B	New Haven	CT	065100000	061582206	501(c)(3)	62500	PPMI 2011: Leadership Core Support for Australia Expansion
The Institute for Neurodegenerative Disorders
60 Temple Street 8th floor	New Haven	CT	065100000	061582206	501(c)(3)	82085	PPMI 2011: Datscan Validation and Regulatory Setup for PPMI Imaging at IND
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	065110000	061582206	501(c)(3)	92813	PPMI Clinical Trial Site - SWEDD Amendment Setup for PPMI Imaging at IND
The Institute for Neurodegenerative Disorders
60 Temple Street Suite 8B	New Haven	CT	065100000	061582206	501(c)(3)	143750	PPMI 2011: SWEDD Sub-Study Support for Imaging Core
The Institute for Neurodegenerative Disorders
60 Temple Street Suite 8B	New Haven	CT	065100000	061582206	501(c)(3)	295867	DAT imaging in unaffected LRRK2 gene positive subjects in a Chinese community cohort
The Institute for Neurodegenerative Disorders
60 Temple St Suite 8B	New Haven	CT	065110000	061582206	501(c)(3)	333750	PPMI Clinical Trial Site: Year Two subjects in a Chinese community cohort blocks alpha-synuclein oligomerization
The Institute for Neurodegenerative Disorders
60 Temple Street Suite 8B	New Haven	CT	065100000	061582206	501(c)(3)	346704	PPMI Leadership Core - Year 2 Funding
The Institute for Neurodegenerative Disorders
60 Temple Street Suite 8B	New Haven	CT	065100000	061582206	501(c)(3)	627434	PPMI Imaging Core - Year 2 Funding disease
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	046090000	010211513	501(c)(3)	21000	LRRK gene Knockout Mice Importing, rederivation, development of allele-specific genotyping assay, crossing to homozygosity, maintaining live colonies, cross LRRK1 and LRRK2 to make double KG, cryopreservation, maintaining colonies
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	046090000	010211513	501(c)(3)	23010	LRRK2 Kinase Dead Mice DNA Preparation, BAC m microinjections, gestation, weaning, and genotyping to identify founders live colonies, cross LRRK1 and LRRK2 to make double KG, cryopreservation, maintaining colonies
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	046090000	010211513	501(c)(3)	67830	Characterization Study -JAX Breeding and Aging microinjections, gestation, weaning, and genotyping to identify founders
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	046090000	010211513	501(c)(3)	81000	shipping and housing of academic models - non LRRK2
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	046090000	010211513	501(c)(3)	81000	shipping and housing of academic models - LRRK2 LRRK2 stimulating alpha4beta2* nAChRs
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	046090000	010211513	501(c)(3)	199000	LRRK2 Knock-In mice - JAX model creation Neurosteroids: A Novel Therapeutic Strategy to Treat Parkinson's Disease
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	046090000	010211513	501(c)(3)	200000	Primary Characterization/selection of Founders of Taconic Lines-mRNA-Protein MJFF7-12
The Jackson Laboratory
610 Main Street	Bar Harbor	ME	046090000	010211513	501(c)(3)	302620	LRRK2 BAC Transgenic mice - Regeneration of Taconic Lines-mRNA-Protein MJFF7-12
The Jackson Laboratory
610 Main Street Bar Harbor Maine 0	Bar Harbor	ME	046090000	010211513	501(c)(3)	348344	Primary Characterization/selection of founders of Taconic Lines-LRRK2
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94089	943061594	501(c)(3)	10000	2011 - Pritzker Prize - runner up of Taconic Lines-LRRK2
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	25443	PPMI Steering Comittee 2011 - Caroline Tanner characterization
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	59438	PPMI Clinical Trial Site - SWEDD Amendment
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	249454	Increasing the Sensitivity of LRRK2 Assays: Development of Proximity Ligation Assays for LRRK2
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94085	943061594	501(c)(3)	251667	Assessment of the pharmacokinetics (PK) and Cognitive Side Effects of the Antidyskinetic Drug Fenobam in MPTP-treated squirrel monkeys
The Parkinson's Institute
675 Almanor Avenue	Sunnyvale	CA	94089	943061594	501(c)(3)	266459	Maintaining of a colony of parkinsonian non- human primates as a resource for pre-clinical drug trials
Trevena Inc
1018 W 8th Ave Ste A	King of Prussia	PA	19406	261469215	Public Sector	205495	Pathway validation of a biased delta opioid receptor ligand for PD symptomatic relief drug trials
UMDNJ-Robert Wood Johnson Medical School-(Universi
683 Hoes Lane Room 180	Piscataway	CA	088540000	237313160	501(c)(3)	274986	The Repositioning of Nalbuphine for the Treat Treatment of LID
University of Alabama at Birmingham
1719 6th Ave S CIRC 516	Birmingham	AL	35294	600539600	501(c)(3)	26425	Characterization of LRRK2 monoclonal antibodies in rodent brain tissue--West
University of Alabama at Birmingham
1719 6th Ave South CIRC 516	Birmingham	AL	352940021	600539600	501(c)(3)	55688	PPMI Clinical Trial Site - SWEDD Amendment in rodent brain tissue--West
University of Alabama at Birmingham
1719 6th Ave S CIRC 560D	Birmingham	AL	35294	600539600	501(c)(3)	125000	14-3-3s as Regulators of LRRK2 Toxicity Detection of Parkinson's Disease
University of Alabama at Birmingham
1719 6th Ave South CIRC 516	Birmingham	AL	352940021	600539600	501(c)(3)	333750	PPMI Clinical Trial Site: Year Two Parkinson's Disease.
University of California Los Angeles
635 Charles E Young Drive South	Los Angeles	CA	900957334	956006143	501(c)(3)	18750	PPMI 2011 - 'Three Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), A Parkinson's Progression Markers Initiative (PPMI) Sub-study' - Support for Bioinformatics Core
University of California Los Angeles
635 Charles E Young Drive South S	Los Angeles	CA	900957334	956006143	501(c)(3)	75000	PPMI 2011: Bioinformatics Core Support for Australia Expansion Biomarker Study (TAP-PD), A Parkinson's Progression Markers Initiative (PPMI) Sub-study' - Support for Bioinformatics Core
University of California Los Angeles
621 Charles E Young Dr South	Los Angeles	CA	90095	956006143	501(c)(3)	98413	A New Strategy to Ameliorate Chemically-Induced Parkinson-like Symptoms by Engaging the Spinal Locomotor Circuitry with Epidural Stimulation
University of California Los Angeles
11301 Wilshire Blvd Bldg 115	Los Angeles	CA	90073	956006143	501(c)(3)	125000	Ghrelin agonist as a novel therapeutic approach to alleviate gut dysmotility and levodopa- inhibited gastric emptying in PD models Stimulation
University of California Los Angeles
635 Charles E Young Drive South S	Los Angeles	CA	900957334	956006143	501(c)(3)	156250	PPMI 2011: SWEDD Substudy Support for Bioinf Bionformatics Core at LONI inhibited gastric emptying in PD models
University of California Los Angeles
635 Charles E Young Drive South S	Los Angeles	CA	900957334	956006143	501(c)(3)	306726	PPMI Bioinformatics Core - Year 2 Funding Bionformatics Core at LONI Tunisia
University of California Los Angeles
650 Charles Young Drive	Los Angeles	CA	900951735	956006143	501(c)(3)	550000	Repositioning BCG vaccination as an Immunostimulant for Slowing the Progression of PD optimization for clinical study
University of California San Diego
9500 Gilman Drive 0662	La Jolla	CA	920930662	952544535	501(c)(3)	55688	PPMI Clinical Trial Site - SWEDD Amendment Immunostimulant for Slowing the Progression of PD efficacy of ADX48621 in the treatment of moderate to severe L-dopa induced dyskinesia in patients with Parkinson's disease
University of California San Francisco
4150 Clement St 114M	San Francisco	CA	94121	946036493	501(c)(3)	62500	PPMI 2011: DTI Core Support for Australia Ex Expansion
University of California San Francisco
505 Parnassus Ave Rm M779	San Francisco	CA	94143	946036493	501(c)(3)	75000	Effect of deep brain stimulation on cortical cross frequency coupling in Parkinson's disease: an electrocorticography study
University of California San Francisco
4150 Clement St 114M	San Francisco	CA	94121	946036493	501(c)(3)	75000	PPMI 2011: SWEDD Addendum -- Support for DTI Core an electrocorticography study Tolerability, and Pharmacokinetics of AZD3241 in Patients with Multiple System Atrophy
University of California San Francisco
600 16th Street MC 2280	San Francisco	CA	941582280	946036493	501(c)(3)	75000	Drug Rescue of PINK1 Kinase Activity - A New Therapeutic Modality For Treating PD
University of California San Francisco
4150 Clement St 114M	San Francisco	CA	94121	946036493	501(c)(3)	102587	PPMI 2011: DTI Analysis Core - Year 2 Funding Therapeutic Modality For Treating PD
University of California San Francisco
4150 Clement St 114M	San Francisco	CA	94121	946036493	501(c)(3)	487211	Multimodal MRI Markers for Parkinson's Disease compound
University of Chicago
5841 S Maryland Avenue MC 2030	Chicago	IL	60637	362177139	501(c)(3)	24821	Development of highly sensitive and specific antibodies against oxidized DJ-1 as a biomarker for Parkinson's disease
University of Chicago
5841 S Maryland Avenue MC 2030	Chicago	IL	60637	362177139	501(c)(3)	221948	Modulation of striatal cholinergic neuronal activity in LID for Parkinson's disease
University of Florida
100 S Newell Dr Room L1-100A	Gainesville	FL	32610	596002052	501(c)(3)	43750	In vivo validation of the AAV-alpha-synuclein vectors generated by UNC for distribution to MJFF supported research community - Mandel Parkinson's disease
University of Florida
2033 Mowry Rd PO Box 103610	Gainesville	FL	32610	596002052	501(c)(3)	250000	The Unfolded Protein Response (UPR) chaperone GRP78/BiP as a therapeutic target for alpha- synuclein toxicity.
University of Iowa
2450 University Capitol Center	Iowa City	IA	52242	426004813	501(c)(3)	15625	PPMI 2011 - Statistic Core Support for 'Three Site Assesment of the Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), A PPMI Sub-study'
University of Iowa
2450 University Capitol Center	Iowa City	IA	52242	426004813	501(c)(3)	81250	PPMI 2011: SWEDD Addendum - Support for Stat Statistics Core Monitoring in a PD Biomarker Study (TAP-PD), A PPMI Sub-study'
University of Iowa
2450 University Capitol Center	Iowa City	IA	52242	426004813	501(c)(3)	210096	PPMI Statistics Core - Year 2 Funding Statistics Core
University of Iowa
2450 University Capitol Center	Iowa City	IA	52242	426004813	501(c)(3)	500261	LRRK2 Cohort Consortium - Statisical Work improvement of regeneration in PD
University of Minnesota
321 Church St Rm 6-145 Jackson Hal	Minneapolis	MN	55455	416007513	501(c)(3)	75000	Alpha-synuclein and tau mislocalization to dendritic spines Parkinson's disease and L-dopa treatment response
University of North Carolina at Chapel Hill
3009 Thurston CB 7178	Chapel Hill	NC	275997178	566001393	501(c)(3)	74402	The Development of Novel Adeno-associated Virus Vectors for Intravenous Parkinson's Gene Therapy Later Life
University of North Carolina at Chapel Hill
Thurston Bowles Building Rm 7119	Chapel Hill	NC	27599	566001393	501(c)(3)	100500	Generation of alpha-synuclein viral vectors Vectors for Intravenous Parkinson's Gene Therapy
University of Pennsylvania
330 South 9th Street	Philadelphia	PA	19104	231352685	501(c)(3)	25188	PPMI 2011: TAP-PD Ancillary Study UPenn alpha-synuclein in the nucleus: DNA binding and transcriptional dysregulation
University of Pennsylvania
330 South 9th Street	Philadelphia	PA	19104	231352685	501(c)(3)	55688	PPMI Clinical Trial Site - SWEDD Amendment L-DOPA-induced dyskinesia
University of Pennsylvania
3400 Spruce Street	Philadelphia	PA	19104	231352685	501(c)(3)	268216	PPMI 2011: Bioanalytics Core - Year 2 Funding alpha-synuclein pathology in rodent brain
University of Pittsburgh
3471 Fifth Avenue	Pittsburgh	PA	15213	250965591	501(c)(3)	73086	Informing clinical decision making in the Pre- motor period of Parkinson disease (PD)
University of Pittsburgh
3501 Fifth Avenue 7039 BST3	Pittsburgh	PA	15260	250965591	501(c)(3)	250000	Phenotypic Characterization of BAC LRRK2 Transgenic Rats in a rat model of Parkinson's disease
University of Pittsburgh
200 Lothrop Street	Pittsburgh	PA	15213	250965591	501(c)(3)	500163	Developing An Alpha-Synuclein Imaging Agent Transgenic Rats treatment of L-DOPA-induced dyskinesias
University of Rochester
919 Westfall Road Building C Suit	Rochester	NY	14618	263800000	501(c)(3)	25000	Langston Award 2011 transfer of alpha-synuclein
University of Rochester
265 Crittenden Blvd	Rochester	NY	14620	263800000	501(c)(3)	34515	Transfer of DATATOP Samples a-synuclein model of PD: implications for the use of GDNF in neuroprotective therapy
University of Rochester
1351 Mt Hope Avenue Suite 216	Rochester	NY	14620	263800000	501(c)(3)	37500	PPMI 2011 -- Three Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), A Parkinson's Progr Progression Markers Initiative (PPMI) Sub-study - Clinical Core funding
University of Rochester
919 Westfall Road Building C Suit	Rochester	NY	14618	263800000	501(c)(3)	55688	PPMI Clinical Trial Site - SWEDD Amendment Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), A Parkinson's Progr Progression Markers Initiative (PPMI) Sub-study - Clinical Core funding
University of Rochester
1351 Mt Hope Avenue Suite 216	Rochester	NY	14620	263800000	501(c)(3)	79285	PPMI 2011: Clinical Core Support for SWEDD and AV-133 Integration
University of Rochester
1351 Mt Hope Avenue Suite 216	Rochester	NY	14620	263800000	501(c)(3)	868085	PPMI 2011: Year 2 Funding - Clinical Coordi Coordination Core
University of South Florida
4001 East Fletcher Avenue 6th Floo	Tampa	FL	33613	593102112	501(c)(3)	92813	PPMI Clinical Trial Site - SWEDD Amendment Coordination Core administration
University of South Florida
4001 E Fletcher Ave MDC36	Tampa	FL	33613	593102112	501(c)(3)	250000	Modulation of Microglial Activation. Progressive Rodent Model of Parkinson?s Disease
University of Southern California
1501 San Pablo St ZNI 111	Los Angeles	CA	90033	951642394	501(c)(3)	75000	Use of HspB1 Chaperone to Inhibit Pathological alpha-Synuclein Aggregation
University of Texas Medical Branch at Galveston
301 University Blvd	Galveston	TX	775551045	746000949	501(c)(3)	75000	Tau oligomers as a potential target for treatment of Parkinson`s disease
University of Utah
15 N 2030 E Rm 2350	Salt Lake City	UT	841125330	876000525	501(c)(3)	75000	Development of dopaminergic cell line models of alpha synuclein expression for high-throughput drug screenings and monitoring of alpha synuclein expression
University of Washington
1660 S Columbian Way	Seattle	WA	98108	916001537	501(c)(3)	55688	PPMI Clinical Trial Site - SWEDD Amendment of alpha synuclein expression for high-throughput drug screenings and monitoring of alpha synuclein expression
University of Washington
1705 NE Pacific St WH Foege Bui	Seattle	WA	98195	916001537	501(c)(3)	74955	How does GBA1 dysfunction influence Parkinson's disease?
University of Washington
325 9th Avenue RM 303B RT Buildi	Seattle	MO	98104	916001537	501(c)(3)	150000	Salivary Biomarkers for Parkinson's disease disease? Stages of Their Extra-Pyramidal Disorder as Part of Their Initial Workup
University of Washington
325 9th Avenue RM 303B RT Buildi	Seattle	MO	98104	916001537	501(c)(3)	204864	Using human cerebrospinal fluid samples collected in DATATOP study for biomarker validation in patients with Parkinson disease
Van Andel Research Institute
333 Bostwick Ave NE	Grand Rapids	MI	49503	522000823	501(c)(3)	400000	Fasudil as a Novel Therapeutic for the Treatment of Parkinson's Disease validation in patients with Parkinson disease
Vanderbilt University
519 Light Hall	Nashville	TN	37232	620476822	501(c)(3)	74999	Whole Exome Sequencing in an Amish Parkinson's Disease Pedigree
Vanderbilt University
23rd Avenue South at Pierce 417-D	Nashville	TN	372326600	620476822	501(c)(3)	315000	Supplement to 'Discovery of mGluR4 Potentiators for Symptomatic and Disease-Modifying Treatment of PD
Wadsworth Center Health Research Inc
120 New Scotland Avenue PO Box 220	Albany	NY	122012002	141402155	501(c)(3)	75000	Developing and characterizing anti-alpha- synuclein nanobodies from an immune phage display library clinical trial in PD patients
Washington University in St Louis
660 S Euclid Campus Box 8111	St Louis	MO	63110	430653611	501(c)(3)	50000	Validation of Neuroimaging Biomarkers for Nigrostriatal Neurons- Supplement 2 display library
Washington University in St Louis
660 S Euclid Campus Box 8111	St Louis	MO	63110	430653611	501(c)(3)	353565	Neurochemical Correlates of Cognitive Phenoty Phenotypes in PD
Washington University in St Louis
510 S Kingshighway Blvd	St Louis	MO	63110	430653611	501(c)(3)	500000	Developing An Alpha-Synuclein Imaging Agent Phenotypes in PD
WIL Research Laboratories
1407 George Road	Ashland	OH	448058946	260564612	Public Sector	28800	Collection and storage of rodent brain and peripheral tissues relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism
WIL Research Laboratories
1407 George Road	Ashland	OH	448058946	260564612	Public Sector	67200	Collection and storage of rodent brain and peripheral tissues - LRRK2
WIL Research Laboratories
1407 George Road	Ashland	OH	448058946	260564612	Public Sector	207000	Characterization Study -WIL Research Mouse and Rat Characterization-LRRK2 disease.
WIL Research Laboratories
1407 George Road	Ashland	OH	448058946	260564612	Public Sector	230000	Characterization Study -WIL Research Mouse and Rat Characterization-ELAN
Yale University
230 South Frontage Road SHM I-269	New Haven	CT	065208047	060646973	501(c)(3)	74165	Role of STriatal-Enriched protein tyrosine Phosphatase 61 (STEP61) in Parkinson's Disease
Zenobia Therapeutics Inc
505 Coast Blvd South Suite 111	La Jolla	CA	92037	262726709	Public Sector	300000	Discovery of LRRK2 target engagement ligands to be used in imaging studies

Field	Value	IRS element (for citing)
Total Nbr Of501 C3 And Govt Grants	61	TotalNbrOf501C3AndGovtGrants
Total Nbr Of Other Organizations	41	TotalNbrOfOtherOrganizations

Form990 Schedule I Part IV Form990ScheduleIPartIV

Field	Value	IRS element (for citing)
Identifier	SCHEDULE I, PART I, LINE 2	Identifier
Return Reference	PROCEDURES FOR MONITORING GRANT FUNDS IN THE UNITED STATES:	ReturnReference
Explanation	THE FOUNDATION AWARDS RESEARCH GRANTS BASED UPON THE GUIDANCE AND INPUT OF THEYSCIENTIFIC ADVISORY BOARD AND OTHER HIGHLY REGARDED SCIENTISTS WHO SERVE ON GRANT REVIEW COMMITTEES SPECIALIZING IN PARKINSON'S RESEARCH. Goals and milestones are described within each grant award. Most Grant awards are allocated in multiple payments with key benchmarks set at the time of the grant award. MJFF's Research team closely monitors the progress of each grant awarded. There is frequent communication between grantees and MJFF staff regarding the progress of each grant. Progress is verified before additional payments are made.	Explanation

Schedule J IRS990ScheduleJ

Field	Value	IRS element (for citing)
Compensation Committee	X	CompensationCommittee
Independent Consultant	X	IndependentConsultant
Form990 Of Other Organizations	X	Form990OfOtherOrganizations
Board Or Committee Approval	X	BoardOrCommitteeApproval
Severance Payment	false	SeverancePayment
Supplemental Nonqual Retire Plan	false	SupplementalNonqualRetirePlan
Equity Based Comp Arrangement	false	EquityBasedCompArrangement
Comp Based On Revenue Of Filing Org	false	CompBasedOnRevenueOfFilingOrg
Comp Based On Revenue Related Orgs	false	CompBasedOnRevenueRelatedOrgs
Comp Based Net Earnings Filing Org	false	CompBasedNetEarningsFilingOrg
Comp Based Net Earnings Relate Orgs	false	CompBasedNetEarningsRelateOrgs
Any Non Fixed Payments	false	AnyNonFixedPayments
Initial Contract Exception	false	InitialContractException

Form990 Schedule J Part II Form990ScheduleJPartII (8 entries)

Base Compensation Filing OrgBaseCompensationFilingOrg	Comp Based On Related OrgsCompBasedOnRelatedOrgs	Bonus Filing OrgBonusFilingOrg	Bonus Related OrgsBonusRelatedOrgs	Other Compensation Filing OrgOtherCompensationFilingOrg	Other Compensation Related OrgsOtherCompensationRelatedOrgs	Deferred Comp Filing OrgDeferredCompFilingOrg	Deferred Comp Related OrgsDeferredCompRelatedOrgs	Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrg	Nontaxable Benefits Related OrgsNontaxableBenefitsRelatedOrgs	Total Compensation Filing OrgTotalCompensationFilingOrg	Total Compensation Related OrgsTotalCompensationRelatedOrgs	Comp Report Prior990 Filing OrgCompReportPrior990FilingOrg	Comp Report Prior990 Related OrgsCompReportPrior990RelatedOrgs
Katherine H Hood
102934	0	173750	0	0	0	0	0	0	0	276684	0	0	0
Todd Sherer
253891	0	135000	0	0	0	7350	0	17303	0	413544	0	0	0
Joanne Martz
207121	0	72000	0	0	0	7350	0	14886	0	301357	0	0	0
Deborah W Brooks
285627	0	188750	0	0	0	7350	0	21052	0	502779	0	0	0
Sohini Chowdhury
178726	0	51300	0	0	0	6901	0	6808	0	243735	0	0	0
Sheila Kelly
148451	0	19500	0	0	0	5039	0	6808	0	179798	0	0	0
Brian K Fiske
160649	0	15500	0	0	0	5015	0	14886	0	196050	0	0	0
Mark A Frasier
152000	0	16750	0	0	0	0	0	0	0	168750	0	0	0

Form990 Schedule J Part III Form990ScheduleJPartIII

Field	Value	IRS element (for citing)
Identifier	DETERMINATION OF COMPENSATION FOR OFFICERS	Identifier
Return Reference	SCHEDULE J, PART I, QUESTION 3	ReturnReference
Explanation	Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually.	Explanation

Schedule L IRS990ScheduleL

Form990 Schedule L Part IV Form990ScheduleLPartIV

Name Of Interested Person NameOfInterestedPerson

Field	Value	IRS element (for citing)
Name Person	Donny Deutsch	NamePerson

Field	Value	IRS element (for citing)
Relationship	Board of Directors	Relationship
Amount Of Transaction	47586	AmountOfTransaction
Description Of Transaction	Design and Creative Services	DescriptionOfTransaction
Sharing Of Revenues	false	SharingOfRevenues

Form990 Schedule L Part V Form990ScheduleLPartV

Field	Value	IRS element (for citing)
Identifier	SCHEDULE L, PART IV	Identifier
Return Reference	BUSINESS TRANSACTIONS INVOLVING INTERESTED PERSONS	ReturnReference
Explanation	THE FOUNDATION INCURRED DESIGN AND CREATIVE ADVICE EXPENSES OF $47,586 FOR SERVICES RENDERED BY A COMMUNICATIONS, BRAND DEVELOPMENT AND DESIGN AGENCY, THE CHAIRMAN OF WHICH IS A FOUNDATION BOARD MEMBER.	Explanation

Schedule M IRS990ScheduleM

Field	Value	IRS element (for citing)
Works Of Art		WorksOfArt
Art Historical Treasures		ArtHistoricalTreasures
Art Fractional Interest		ArtFractionalInterest
Books And Publications		BooksAndPublications
Clothing And Household Goods		ClothingAndHouseholdGoods
Cars And Other Vehicles		CarsAndOtherVehicles
Boats And Planes		BoatsAndPlanes
Intellectual Property		IntellectualProperty

Securities Publicly Traded SecuritiesPubliclyTraded

Field	Value	IRS element (for citing)
Non Cash Checkbox	X	NonCashCheckbox
Number Of Contributions	43	NumberOfContributions
Noncash Contribs Rptd F990	28138747	NoncashContribsRptdF990
Method Of Determining Revenues	FAIR VALUE	MethodOfDeterminingRevenues

Field	Value	IRS element (for citing)
Securities Closely Held Stock		SecuritiesCloselyHeldStock
Securities Prtnrshp Trust Intrsts		SecuritiesPrtnrshpTrustIntrsts
Securities Miscellaneous		SecuritiesMiscellaneous
Qualified Contrib Hist Struct		QualifiedContribHistStruct
Qualified Contrib Other		QualifiedContribOther
Real Estate Residential		RealEstateResidential
Real Estate Commercial		RealEstateCommercial
Real Estate Other		RealEstateOther
Collectibles		Collectibles
Food Inventory		FoodInventory
Drugs And Medical Supplies		DrugsAndMedicalSupplies
Taxidermy		Taxidermy
Historical Artifacts		HistoricalArtifacts
Scientific Specimens		ScientificSpecimens
Archaeological Artifacts		ArchaeologicalArtifacts
Number Of8283 Received	0	NumberOf8283Received
Any Property That Must Be Held	false	AnyPropertyThatMustBeHeld
Review Process Unusual NC Gifts	true	ReviewProcessUnusualNCGifts
Third Parties Used	false	ThirdPartiesUsed

Schedule O IRS990ScheduleO

General Explanation GeneralExplanation (3 entries)

IdentifierIdentifier	ExplanationExplanation	Return ReferenceReturnReference
FORM 990, PAGE 1, LINE 1 AND PAGE 2, LINE 1	FINDING THE CURE FOR PARKINSONS TAKES AN ORGANIZATION WITH EXTRAORDINARY VISION. Actor Michael J. Fox established The Michael J. Fox Foundation for Parkinson's Research (the "Foundation"), incorporated in Delaware in 2000, after publicly disclosing in 1998 that he had been diagnosed with Parkinson's disease seven years earlier at age 29. In 2009, The Michael J. Fox Foundation for Parkinson's Research in Canada ("MJFF Canada") was established as an officially registered tax-exempt charity in Canada. As this entity meets the criteria for consolidation, its financial statements are consolidated with those of the Foundation. As MJFF Canada's assets and liabilities and its operations were not significant at December 31, 2011 and 2010, they are not shown separately in the accompanying consolidated financial statements. The Foundation is exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code, and from state and local taxes under comparable laws. MJFF Canada is exempt from similar taxes under Canadian law. Today, The Michael J. Fox Foundation is the world's largest private funder of Parkinson's research. It is dedicated to accelerating a cure for Parkinson's disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson's patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $288 million in research as of December 31, 2011, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson's research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson's disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson's awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world. In addition to funding a broad portfolio of investigator-initiated and priority-driven research programs, the Foundation is working to transform the medical research enterprise and shape a system that fosters, rather than inhibits, the development of cures. MJFF partners with the Parkinson's research community, speeding financial and intellectual resources to the scientists who can help realize ideas with the greatest promise to impact patients' lives. The Foundation has ignited collaboration among academic and industry players by requiring researchers to share information in real time. To enable scientists to move toward breakthroughs faster, MJFF has stepped up to meet their need for research tools. To date, the Foundation has funded work on over 100 therapeutic targets, and is currently supporting over 20 clinical trials. Since its founding, MJFF has proven not only that a new kind of stakeholder can accelerate drug development - but that it is what was missing all along. While much has changed in the past decade, one thing remains constant: the Foundation's commitment o Parkinson's patients. Everything MJFF does is with patients in mind, at all stages of PD, which informs investments in disease-modifying therapies, better symptomatic treatments and new approaches to the symptoms entirely unaddressed by today's generation of drugs.
Form 990, Page 6	Line 2: TWO BOARD MEMBERS ARE MARRIED TO ONE ANOTHER. TWO BOARD MEMBERS ARE IN-LAWS. Line 11A: Process for Review of Form 990: The Finance Committee of the Board of Directors, in association with external auditors, approves the annual IRS Form 990 which is then made available to the entire Board before it is filed. Line 12A: Conflict of Interest Policy monitoring: Officers, directors and key employees complete a conflict of interest questionnaire annually. The information is reviewed by the Chief Financial and Administrative Officer, and conflicts are reviewed with the Board of Directors. Line 15: Compensation Determination: The Compensation Committee of the Board of Directors reviews and approves compensation of key employees annually. Line 19: Governing documents are available upon request. - Conflict of interest policy is available upon request. - Financial statements are available at www.michaeljfox.org.	Governance, Management and Disclosure
Form 990, PAGE 12, LINE 5	OTHER CHANGES IN NET ASSETS IS ATTRIBUTABLE TO UNREALIZED LOSSES OF $10,721.	OTHER CHANGES IN NET ASSETS

Schedule R IRS990ScheduleR

Form990 Schedule R Part II Form990ScheduleRPartII

Name Of Disregarded Entity NameOfDisregardedEntity

Field	Value	IRS element (for citing)
Business Name Line1	MJFF CANADA	BusinessNameLine1

Address Foreign AddressForeign

Field	Value	IRS element (for citing)
Address Line1	365 Bay Street Suite 899	AddressLine1
City	Toronto	City
Province Or State	Ontario	ProvinceOrState
Country	CA	Country

Field	Value	IRS element (for citing)
Primary Activities	RESEARCH	PrimaryActivities
Legal Domicile Foreign Country	CA	LegalDomicileForeignCountry

Direct Controlling Entity Name DirectControllingEntityName

Field	Value	IRS element (for citing)
Business Name Line1	MJFF (US)	BusinessNameLine1

Field	Value	IRS element (for citing)
Receipt Of Int Ann Rents Royalties	false	ReceiptOfIntAnnRentsRoyalties
Gift Grant Or Cap Contr To Other Org	false	GiftGrantOrCapContrToOtherOrg
Gift Grant Or Cap Contr Fr Other Org	true	GiftGrantOrCapContrFrOtherOrg
Loans Or Guarantees To Other Org	false	LoansOrGuaranteesToOtherOrg
Loans Or Guarantees From Other Org	false	LoansOrGuaranteesFromOtherOrg
Sale Of Assets To Other Org	false	SaleOfAssetsToOtherOrg
Purchase Of Assets From Other Org	false	PurchaseOfAssetsFromOtherOrg
Exchange Of Assets	false	ExchangeOfAssets
Rental Of Facilities To Other Orgs	false	RentalOfFacilitiesToOtherOrgs
Rental Of Facilities Fr Other Orgs	false	RentalOfFacilitiesFrOtherOrgs
Perform Of Services For Other Orgs	false	PerformOfServicesForOtherOrgs
Perform Of Services By Other Orgs	false	PerformOfServicesByOtherOrgs
Sharing Of Facilities	false	SharingOfFacilities
Sharing Of Paid Employees	false	SharingOfPaidEmployees
Reimbursement Paid To Other Org	false	ReimbursementPaidToOtherOrg
Reimbursement Paid By Other Org	false	ReimbursementPaidByOtherOrg
Other Transfer To Other Org	false	OtherTransferToOtherOrg
Other Transfer From Other Org	false	OtherTransferFromOtherOrg

Transactions Related Orgs Table TransactionsRelatedOrgsTable

Name Of Other Organization NameOfOtherOrganization

Field	Value	IRS element (for citing)
Business Name Line1	THE MICHAEL J FOX FOUNDATION (CANADA)	BusinessNameLine1

Field	Value	IRS element (for citing)
Transaction Type	C	TransactionType
Amount Involved	2277800	AmountInvolved